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Abstract 			
Subclinical ascorbate deficiency is widespread in many populations, but its role in both 
Alzheimer’s disease and normal aging is understudied. We decreased brain ascorbate in the 
APPSWE/PSEN1deltaE9 mouse model of Alzheimer’s disease by crossing APP/PSEN1+ bigenic 
mice with SVCT2+/− heterozygous knockout mice, which have lower expression of the 
sodium-dependent vitamin C transporter required for neuronal ascorbate transport. At 6 
months, SVCT2+/− and APP/PSEN1 mice and the combination genotype 
SVCT2+/−;APP/PSEN1 were impaired on multiple tests of cognitive ability and exhibited 
increased oxidative stress in the brain. Increased amyloid plaque burden was observed in 
SVCT2+/−;APP/PSEN1 mice compared to APP/PSEN1 mice at 14 months. At 4 months of 
age, during what is considered a prodromal stage in mouse models of Alzheimer’s disease, 
mitochondria isolated from SVCT2+/− and APP/PSEN1 mice showed disruptions in oxygen 
consumption and mitochondrial respiration with opposing directionality indicating that different 
pathways were being affected. Both groups had significant increases in the production of 
reactive oxygen species. Additionally, genes commonly associated with Alzheimer’s disease 
pathology and progression were up-regulated in SVCT2+/−;APP/PSEN1 mice and 
APP/PSEN1, with a greater magnitude of gene expression change in SVCT2+/−;APP/PSEN1 
mice. Furthermore, 5-hydroxymethylcytosine levels, indicative of epigenetic modification, 
were significantly increased compared to wild type at 4 months. There were differing patterns 
of gene expression based on SVCT2+/− and APP/PSEN1 status, as well as with age, 
suggesting an age-related change in gene expression occurs earlier in APP/PSEN+ groups 
and is exacerbated in combination with ascorbate deficiency. These data support the 
hypothesis that even moderate ascorbate deficiency plays an important role in accelerating 
amyloid pathogenesis, particularly during early stages of disease development, and that 
oxidative stress pathways likely modulate these effects.  
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Chapter I: Introduction 		
The multifaceted etiology of Alzheimer’s disease 	
 
The amyloid cascade hypothesis 
Alzheimer’s disease (AD) is a significant public health concern in the United States, 
with projected health care costs reaching trillions of dollars over the next few decades. More 
than 90% of AD cases occur with no identifiable cause. For many years the leading dogma in 
the field of AD research, referred to as the “amyloid cascade hypothesis”, suggested that the 
accumulation of amyloid beta (Aβ) and hyperphosphorylated tau peptides are toxic to the 
brain environment leading to global loss of neurons [1]. These histopathological hallmarks, 
and mild cognitive impairment in most cases, persist today as the criteria for diagnosis of the 
disease, but neither has been definitively affirmed as the solely or specifically cause or 
consequence of the disease. Ab is produced by cleavage of the transmembrane amyloid 
precursor protein (APP) by secretase enzymes [2]. Under normal conditions, APP is cleaved 
by a- and g-secretase; however, a shift to the amyloidogenic cleavage of APP by b- and g-
secretase results in 38-43 amino acid Ab peptides that aggregate to form insoluble oligomers, 
which are toxic to cells [3]. The second major histopathological hallmark of AD is the 
hyperphosphorylation of tau. This inhibits the ability of the tau proteins to stabilize 
microtubule assembly and promotes neurofibrillary tangles [2,4], which disrupt intracellular 
transport [5]. A significant caveat is that some individuals who appear to be at a greater risk 
for dementia, or already exhibit substantial Aβ plaques and neurofibrillary tangles, never 
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experience cognitive decline [1,6], suggesting these pathological features alone do not 
correlate to cognitive impairment [7–9].  
 
The mitochondrial cascade hypothesis 	
Mitochondria are highly oxidative organelles capable of producing large amounts of 
reactive oxygen species (ROS), and mitochondrial dysfunction is observed in several 
neurological diseases [10,11]. According to the “mitochondrial cascade hypothesis” of AD, 
age-related mitochondrial dysfunction elevates levels of ROS. Along with age-related 
decreases in the activity of endogenous antioxidant enzymes, this leads to a redox imbalance 
in the brain capable of driving AD pathology by up-regulating Aβ production and tau 
phosphorylation [12–15]. The consequences of this dysfunction are a reduction in available 
energy for proper cellular function and activation of mitochondria-mediated apoptotic 
pathways. Even with multiple mitochondria within a neuron, oxidative damage can cause a 
collapse of mitochondrial membrane potential and mitochondrial DNA mutations that 
compromise complexes I, III, IV of the electron transport chain and ATP synthase [4,10,14], 
leading to a progressive disruption of energy production through mitochondrial proliferation 
that emerges before the classical pathological features of AD.  
 
Structural and functional alterations in mitochondria in Alzheimer’s disease 
Mitochondria have highly specialized structural morphology that dictate both function 
and productivity, but it is the balance between fusion and fission events that governs health of 
mitochondria within a cell [16]. Fusion between two mitochondria compensates for 
deficiencies in function because it allows for the sharing of mitochondrial DNA and membrane 
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proteins that may have become damaged over time. Conversely, fission facilitates the 
recycling of irreversibly damaged mitochondria through autophagy of the organelle, or 
mitophagy. In mouse models of AD, Aβ peptides interact with and alter mitochondrial 
structure and function before significant plaque deposition is observed [17]. Intracellular 
accumulation of Aβ peptides localizes with mitochondrial markers and appears to enter 
mitochondria through translocase machinery on the outer membrane [18]. Choi et al. report 
that hippocampal mitochondria in 7-month-old APP/PSEN1 mice, a mouse model of AD, 
exhibited bulging outer membranes along with misshapen and absent cristae, but the same 
was not observed in age-matched wild type mice [19]. Genes associated with mitochondrial 
biogenesis and replication, and complexes I-IV which are necessary for oxidative 
phosphorylation were down-regulated in the hippocampi of 3-month-old APP/PSEN1 mice 
compared to age-matched wild type mice [17], suggesting diminished energy metabolism at 
very early stages of the disease. Additionally, an increase in fission gene expression and a 
decrease in fusion gene expression were reported in post-mortem brain specimens from 
patients with early and late stage AD [20,21] indicating a shift toward mitochondrial fission 
and increases in mitochondrial DNA oxidation in patients with mild cognitive impairment and 
early-stage AD [13]. Animal models of AD exhibit similar morphological alterations as well as 
decreased levels of mitochondrial fusion proteins and increased levels of fission proteins at 
early stages of disease progression [22]. The accumulation of Aβ peptides by the 
overexpression of the APP in the Arctic APP mouse model decreased ATP production, 
impaired mitochondrial membrane potential, and inhibited complex IV activity, in addition to 
exacerbating oxidative stress [11,23]. While the relationship between mitochondrial 
dysfunction and AD pathology has yet to be clearly defined, once established this relationship 
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becomes cyclical: mitochondrial dysfunction increases ROS production and creates an 
energy deficit for protein degradation leading to an accumulation of toxic Aβ, which then 
contributes to further oxidative damage capable of inducing cell death. 
 
Contribution of oxidative stress 
Technological advances improve our ability to isolate key pathological, cellular and 
molecular changes that accompany both the inherited and sporadic forms of AD to identify 
very early stages of disease, particularly in at-risk individuals, sometimes decades before the 
clinical manifestation of cognitive dysfunction [1,24]. Oxidative stress, which is defined as an 
imbalance in the homeostatic relationship between oxidation species and antioxidant 
defenses, manifests as oxidative damage to lipids, proteins and nucleic acids. This oxidative 
damage contributes to the development and progression of AD pathology and can cause 
significant alterations to downstream mechanisms involved in energy metabolism and 
proteolysis, thus compromising cellular repair mechanisms [25–27].  
Alterations in gene expression occur with age [28]; however, even greater changes in 
expression of genes involved in oxidative stress, amyloid beta production and inflammation 
are observed in AD patients compared with controls [29]. Studies show that oxidative stress 
increases the expression of presenilin-1 (PSEN1), and BACE1, both of which are major 
components of the two secretase enzymes responsible for amyloidogenic cleavage of the 
APP [30–32]. Aβ peptides are produced and degraded under normal conditions throughout 
life; however, increasing evidence has implicated Aβ oligomers in the neurotoxicity 
associated oxidatively modified molecules [33,34]. Li et al. reported hippocampal neurons 
treated with glycated Aβ, a result of protein oxidation, showed decreased viability, increased 
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tau hyperphosphorylation and apoptosis compared to neurons treated with Aβ alone [35]. 
Consistent with evidence that chronic neuroinflammation is observed in AD, ROS can also 
trigger the release of inflammatory cytokines, which themselves contribute to oxidative stress, 
fueling a damaging feedback cycle [36,37].  
Lipid peroxidation refers to the degradation of lipids following oxidative attack. Clinical 
studies indicate lipid peroxidation is elevated as a result of age, with even greater increases 
observed in AD brains compared with age-matched controls [38,39]. Lipid peroxidation end 
products, such as isoprostanes, malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE) are 
highly reactive and disrupt normal cellular function [40]. Aβ-induced cell death also appears 
to be mediated through 4-HNE [31], by activation of the caspase cascade and mitochondria-
mediated apoptotic pathways [41,42]. Several studies show that 4-HNE is able to bind to and 
inhibit membrane components such as glucose and glutamate transporters [43,44], and Na/K 
ATP-ase [45], resulting in structural alterations, loss of function and resistance of 
dysfunctional proteins to degradation [27]. Redox proteomics studies in AD brains have 
identified oxidatively modified proteins associated with ATP production and proteasome 
activity [46]. These findings are consistent with the decreased energy metabolism and 
accumulation of damaged proteins due to deficient degradation observed in the brains of AD 
patients [6]. 
 
Vitamin C: a therapeutic strategy for protection 
Current interventions do not address the role of oxidative stress in AD pathogenesis or 
progression, but preventative strategies to delay pathological decline by attenuating oxidative 
stress may delay age of onset of cognitive decline. Interventions after the onset of clinical 
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symptoms, such as impaired memory and reasoning, are far more challenging due to the 
extent of damage, whereas preventative strategies to delay pathological decline would also 
delay age of onset of cognitive decline. The activity of endogenous antioxidant enzymes and 
levels of nutrient-based antioxidants are significantly reduced in early and late stages of AD 
[12]. While little can be done to increase levels of endogenous antioxidants in AD patients, 
proper diet and supplementation can easily and efficiently reinforce a depleted antioxidant 
barrier. Vitamin C, known as ascorbate (ASC) when referring to activity or biosynthesis within 
the body, is an extraordinarily powerful, water-soluble antioxidant capable of reducing most 
oxidant species due to its the low reduction potential [47]. The abbreviation “ASC” will be 
used to described vitamin C moving forward in this document. ASC scavenges aqueous free 
radicals, such as ROS and reactive nitrogen species, which cause oxidative damage to 
proteins, nucleic acids and lipids. ASC also recycles vitamin E, a lipophilic antioxidant, 
thereby supporting the overall redox balance in the body and preventing oxidative stress.  
 
ASC transport and metabolism 
ASC is absorbed into the bloodstream from ingested food through the sodium-
dependent Vitamin C transporter, type 1 (SVCT1) which is primarily expressed in the 
intestines and kidneys. ASC is taken up by most tissues on the ubiquitously expressed 
sodium-dependent vitamin C transporter, type 2 (SVCT2), which has a higher affinity for ASC 
[48]. SVCT2 transports ASC from the bloodstream into cerebrospinal fluid at the choroid 
plexus and then into neurons. In humans, typical plasma concentrations range from 40-60μM 
and cerebrospinal fluid concentrations range from 100-200μM [48]. Tissue concentrations, 
diagrammed in Figure 1, differ based on the type and amount of transporter expressed, 
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which is ultimately determined by specific tissue requirements. The highest concentrations of 
ASC in the body are found in the brain, which is particularly vulnerable to oxidative damage 
because of its enriched lipid composition and significant oxygen consumption [36]. The brain 
is highly metabolically active compared to the periphery, which generates higher 
concentrations of ROS, however the brain has lower concentrations of enzymatic 
antioxidants compared to the periphery, supporting the requirement for additional antioxidant 
resources [12]. Neuronal concentrations (2-10mM) are as much as ten-fold greater than glial 
concentrations (1mM) and concentrations across different brain areas also differ, presumably 
due to higher rates of metabolism [47,49,50].   
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Figure 1. ASC concentrations are determined by SVCT distribution. Michels, A., Frei, B. (2017, Feb. 26) Vitamin C.  
Retrieved from www.basicmedicalkey.com/vitamin-c/ 
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Several intracellular recycling mechanisms exist in the brain in order to maintain such 
high concentrations [47] (Fig. 2).  Ascorbic acid is oxidized to the ascorbate free radical 
(AFR) by scavenging ROS and reactive nitrogen species, or through enzymatic activity. 
NADH/NADPH-dependent enzymes and glutathione can reduce AFR, and AFR molecules 
preferentially react with one another to produce a reduced ascorbic acid molecule and a 
twice-oxidized dehydroascorbate (DHA) molecule via a dismutation reaction. DHA has a half-
life of only 6 minutes at physiological pH, which accounts for the gradual loss of ascorbic acid 
stores in the body. DHA can be transported in and out of cells on the GLUT transporters and 
reduced to ascorbic acid by NADPH-dependent enzymes and glutathione. In fact, astrocytes 
do not express SVCT2 endogenously, but accumulates ascorbic acid by taking up and 
recycling DHA. Astrocytes exhibit a synergistic hetero-exchange of glutamate uptake and 
ascorbic release, presumably to maintain redox balance at the level of the synapse [48].  
 
																									 	
Figure 2 Ascorbic acid oxidation and reduction. Ascorbic acid is recycled from the ascorbate free radical 
(AFR) and dehydroascorbate (DHA) through enzymatic and dismutation reactions. 
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ASC as an enzymatic co-factor 
ASC has an established function as a co-factor in 2-oxoglutarate-dependent 
dioxygenases enzymes, which require 2-oxoglutarate and iron to incorporate oxygen into 
molecules. It is proposed that ASC prevents inhibitory self-oxidation in these enzymatic 
reactions [51]. This family of enzymes are involved in several biochemical pathways including 
synthesis of essential molecules and catecholamines, cell signaling and gene transcription, 
and DNA demethylation [52]. ASC supplementation reduced DNA damage following 
carcinogenic or mutagenic exposure [53]. ASC concentrations in the brains of mice and rats 
are highest perinatally [50,54], and several studies have shown that cellular reprogramming 
via demethylation is impacted by the availability of ASC [55–58]. The addition of ASC to stem 
cells and mouse embryonic fibroblasts promotes DNA demethylation and histone modification 
suggesting an important epigenetic role during development.  
 
ASC and oxidative stress 
As little as a 30% deficiency of ASC in brain induces oxidative stress in mice whether 
from decreased expression of SVCT2, the sole ASC transporter expressed in the central 
nervous system [59,60], or decreased dietary intake in mice that lack the ability to synthesize 
AA in the liver (gulo-/-) [61,62]. Our research group first established elevated markers of 
oxidative stress and sensorimotor deficits in gulo-/- mice even after supplementation to 
restore physiological ASC levels [60,62], indicating lasting changes to physiology. In a follow-
up study conducted by Harrison et al., ASC fell precipitously in the cortex of non-
supplemented gulo-/- pups between P1 (5.5umol/g) and P18 (1.5umol/g), indicating 
significant ASC turnover in the brain. Interestingly, no significant difference in MDA levels, a 
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marker of lipid peroxidation, was observed in the cortex of gulo-/- pups compared with 
littermate controls, which may account for the rapid decrease in ASC concentration. One 
caveat to consider is that genetic manipulation, though a powerful experimental tool, does not 
account for changes to synergistic mechanisms that occur through evolution. Guinea pigs, 
like humans, cannot synthesize ASC due to an evolutionary mutation in the gene for L-
gulono-g-lactone oxidase (gulo). This model may resemble homeostatic regulation of ASC 
and deficiency in humans more closely than the gulo-/- mouse model. Paidi et al. investigated 
the effects of pre- and post-natal ASC deficiency and repletion on MDA levels in the brains of 
gestationally-depleted guinea pigs [63]. Brain and plasma ASC concentrations were 
significantly lower, while MDA levels were significantly higher in the depleted condition 
compared with the repleted condition. Importantly, no significant difference was observed on 
any measure in repleted animals compared with control, which highlights mechanistic 
differences between the guinea pig and mouse models. Guinea pigs may have better 
oxidative damage repair mechanisms in repleted conditions that co-evolved with L-gulono-g-
lactone oxidase inactivation. 
In human studies, ASC supplementation of at least 250mg per day increased plasma 
concentrations of ASC and lowered markers of systemic lipid peroxidation in all participants 
[64]. Additionally, studies in which ASC supplementation resulted in plasma concentration 
that were consistently greater than 50μmol/L decreased markers of oxidative damage to DNA 
such as chromosomal abnormalities, DNA adducts, and DNA strand breaks, while increasing 
markers of DNA repair mechanisms. These data support a direct relationship between 
oxidative stress and ASC deficiency, and the protective role ASC has in the body. ASC 
supplementation provides a potential strategy to slow the progression of AD by attenuating 
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the damaging effects of oxidative stress and may prove to be a valuable addition to current 
therapies. 
 
ASC attenuates Alzheimer’s disease pathology 
Clinical studies suggest nutrient-based antioxidant supplementation, including vitamins 
C and E, confers some protection against cognitive decline associated with AD [65–68]. A 
meta-analysis evaluating oxidative stress biomarkers confirmed decreased antioxidant 
capacity in the plasma of patients with AD, suggesting that antioxidant defenses are being 
consumed more rapidly in these individuals because of increased oxidative stress associated 
with AD [39]. In in vitro studies, Aβ-induced cell death is mediated via oxidative stress 
[41,42], tying the etiological pathways together. Animal studies offer more definitive evidence 
that ASC not only ameliorates oxidative stress, but also inhibits the production of Aβ [69–73]. 
Acute administration of ASC improved cognitive deficits in AD mouse models without 
affecting plaque formation [74,75]. Dietary treatments with vitamins C, E and other 
antioxidants have been shown to rescue memory impairments in rodents with oxidative stress 
and learning deficits due to APP and PSEN1 mutations, melamine treatment, and hypoxia 
[76–79]. Similarly, vitamin E supplementation to Tg2576 mice decreased oxidative stress in 
the brain and decreased Aβ1-40 and Aβ1-42 levels, but the latter effects were found only when 
supplements were started before 6 months of age, not in an older cohort that were treated 
from 14 months [80]. Six months of a medical food cocktail containing vitamins C and E, 
among several other constituents, also decreased soluble and insoluble Aβ1-40 as well as 
soluble Aβ1-42 in Tg2576 mice [81]. Three months of a combination diet combining 
antioxidants (including vitamins C and E), plus a number of items specifically designed to 
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stimulate synaptic membrane formation, decreased both Aβ1-40 and Aβ1-42 in APP/PSEN1+ 
mice at 6 months of age [82].  
A study by Murakami et al. investigated chronic ASC administration and Ab pathology 
in the AbPP transgenic AD mouse model. In this study, mice were treated with ~1000mg of 
ASC daily through ad libitum access to supplemented drinking water for six months [69]. At 
twelve months of age, the mice were assessed for differences in oxidative stress and AD 
pathology, with particular interest in Ab assembly. As expected, the ASC-treated group 
showed decreased levels of protein carbonylation, as a marker of oxidative stress, and 
increased glutathione, an endogenous antioxidant capable of recycling ASC. Interestingly, 
ASC-treated mice showed a decrease in total soluble Ab42 (ELISA), Ab dimers (ELISA, 
Western blot) and phosphorylated tau protein (Western blot) compared with vehicle-treated 
mice. Congruent with studies employing acute ASC administration, chronic ASC 
supplementation did not alter plaque formation in AbPP mice  (Murakami, 2011). The ASC-
treated AbPP group performed more like wild-type controls on Y-maze tasks than did the 
vehicle-treated AbPP group; with no observed improvement on memory tasks (Murakami, 
2011). Kook et al. reported similar histopathological results using a gulo-/-;5XFAD transgenic 
AD mouse model [70]. In this study, higher ASC supplementation (3.3g/L) reduced overall 
amyloid plaque burden. This finding is inconsistent with the studies discussed above; 
however, the mice in this study began supplementation much earlier and carry a greater 
mutation burden for a more severe phenotype. The authors from either study did not venture 
to characterize a mechanism by which ASC is protective; however the presence of oxidants 
has been shown to induce Ab and neurofibrillary tangle assembly. Thus, ASC may prevent 
AD pathology by scavenging reactive species before they impact Ab and tau pathologies. 
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ASC at the subcellular level 
SVCT2 co-localizes with several organelle markers and compartmentalized increases 
in ASC concentration indicate a specific requirement for ASC at the subcellular level 
[reviewed in 76]. As discussed previously, ASC plays a role in differentiation and epigenetic 
modification based on its role as an enzymatic co-factor, many of which are localized to the 
nuclear compartment. SVCT2 also co-localized with proteins of the endoplasmic reticulum, 
which also utilizes 2-oxoglutarate-dependent dioxygenases enzymes in protein biosynthesis 
[84]. Of particular interest, the localization of SVCT2 on mitochondria isolated from guinea pig 
liver was first identified in a study published in 1982 [85]. This study not only reported that 
mitochondrial membranes were permeable to DHA in the presence of the ascorbate oxidase 
enzyme, as determined by HPLC, but also that ASC concentrations in isolated mitochondria 
reflected the ASC concentration in which they were incubated suggesting that DHA transport 
and recycling was not the primary mode ASC accumulation. Recent reports show SVCT2 
expression in mitochondria maintains kinetics similar to SVCT2 in plasma membranes in cell 
lines [86,87]. With regard to the relationship between mitochondria and AD pathogenesis, in 
addition to reducing plaque burden, Kook et al. found pronounced morphological changes in 
mitochondria from gulo-/-;5XFAD mice on low ASC supplementation compared with the high 
supplementation group suggesting ASC is necessary for maintaining mitochondrial integrity 
by mitigating oxidative damage to the organelle [70]. What is still unknown is how ASC 
deficiency can compromise cellular function at the subcellular level within the context of 
disease outcomes.  
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Significance 
 
Alzheimer’s disease is a balance of risk and benefit 
Risk factors most closely associated with increased risk of developing AD include age, 
genetic markers [88], family history [13] and environmental or lifestyle choices. Low 
socioeconomic status, which is associated with increased AD risk factors, such as decreased 
access to education and increased reports of chronic stress, have also been shown to 
correlate with poor nutrition from development throughout life [89]. In contrast, years of 
education, avoiding social isolation and regular exercise are strongly associated with 
decreased risk. Adherence to the Mediterranean diet, which emphasizes high intake of fruits 
and vegetables and unsaturated fatty acids, reduces risk of developing AD, indicating that 
nutrition plays an important role in modifying risk [88,90–92]. The “threshold to disease” 
concept is often applied to conditions in which no single etiology has been identified: it is the 
additive effect of risk factors and risk modifiers that ultimately confers individual risk for 
disease and the impact that pathological changes have on cognitive function. This balancing 
of risk factors and risk modifiers suggests that alternative pathways may be the driving force 
behind degeneration observed in Alzheimer’s disease. ASC is essential to maintaining 
normal biological function and the cellular redox balance; therefore, life-long maintenance of 
adequate ASC concentration can act as a risk modifier for AD.  
 
ASC deficiency is a public health issue 
The most severe form of ASC deficiency is most commonly associated with ocean 
voyages and sailors developing scurvy, a disease in which collagen is destabilized by the 
lack of ASC. The earliest descriptions of the disease were documented in records as far back 
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as Hippocrates, but it was not until the 18th century that scurvy prevention was linked to diet, 
specifically to ascorbic acid [93]. While a very low daily dose (10mg/d) is sufficient to prevent 
scurvy [94,95], ASC deficiency is common due to advanced disease (e.g. cancer and 
neurodegenerative diseases), lifestyle choice and food insecurity, which is defined by the 
USDA as anything from reduced quality or variety of nutritious food to disrupted or 
inadequate food intake. Affordable, shelf stable foods are often calorie dense but do not 
provide adequate nutrition. ASC depletion (defined as lower than 28 μM) is typically found in 
10-30% of populations, and cases of extreme deficiency (<11 μM) are also reported, with 
low-income and elderly individuals being at even greater risk [96–99]. GWAS studies report 
that SVCT polymorphisms can alter dietary ASC absorption and are associated with lower 
concentrations in biological fluids [100–102]. While the brain can preferentially store and 
recycle ASC under conditions of inadequate intake, in extreme deficiency conditions, or 
under prolonged periods of deficiency, these mechanisms are unable to maintain sufficient 
ASC concentrations. ASC deficient individuals are vulnerable to oxidative stress, which 
renders these individuals more vulnerable to developing disease with more rapid decline and 
poorer outcomes.  
 
Contributions to the field 
 The research described herein was designed to investigate the role of ASC deficiency 
in impaired mitochondrial function and oxidative stress, and how these events contribute to 
sub-cellular damage and genetic modification associated with AD-related neurodegeneration. 
To date, very few studies have addressed deficiency, rather opting for ASC supplementation 
in attenuating disease pathology. We are well-equipped to conduct this research because we 
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are the only lab to maintain colonies of all known mouse models of ASC deficiency and 
altered transporter expression, whereas supplementation studies have been critically limited 
by the use of rodent models that cannot become deficient due to conserved ASC 
biosynthesis and transport. Using a genetic modification to disrupt ASC transport in the brain 
(SVCT2+/-), we have modeled the effects of human ASC deficiency in AD using the 
APPSWE/PSEN1dE9 (APP/PSEN1) mouse model that predisposes mice to the development Aβ 
pathologies. Chapter III highlights a direct relationship between ASC deficiency and the 
oxidative stress and cognitive decline associated with AD pathology. Chapter IV addresses 
the effects of ASC deficiency and Aβ pathologies on mitochondrial activity: specifically, 
oxygen consumption, mitochondrial membrane potential and the generation of ROS. Lastly, 
Chapter V details the role of ASC deficiency in the expression of AD-related genes. The 
ultimate goal of this work is to establish adequate ASC intake as an effective and inexpensive 
path to life-long brain health and a necessary preventative strategy against 
neurodegenerative disease, as well as offer new avenues for targeted interventions.  
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Chapter II: Materials and Methods 
 
Animals 	
 All animals were housed in a temperature and humidity controlled vivarium and were kept on 
a 12:12 hour light cycle. Female C57Bl/6J wild-type mice 
(http://jaxmice.jax.org/strain/000664.html) and male bigenic APPSWE/PSEN1ΔE9 mice 
(http://jaxmice.jax.org/strain/005864.html) were obtained from Jackson Laboratories and used 
to found the colonies used in this study. SVCT2+/- mice have decreased expression of the 
SVCT2 transporter and 20-30% decreased brain vitamin C levels although they retain the 
ability to synthesize vitamin C, and peripheral SVCT2-dependent tissue contents are within 
50-90% of SVCT2+/+ littermates [59]. These mice were originally obtained from Dr. Robert 
Nussbaum. They were backcrossed at least 10 generations to the C57Bl/6J strain and 
maintained on that same background. SVCT2 transgenic mice (SVCT2Tg) used in Chapter 4 
were developed for our research group, and exhibit a global increase in SVCT2 expression 
and concomitant increases in ASC concentration [103]. For simplicity we use the term “wild-
type” to denote mice that do not carry the mutations APP and PSEN1. Mice that are wild-type 
for SVCT2 will be described using “SVCT2+/+” or by describing their vitamin C levels (normal 
vitamin C versus low vitamin C in the SVCT2+/- mice). All procedures were approved by the 
Vanderbilt Institutional Animal Care and Use Committee. 
 
Methods for Chapter 3 
For Chapter 3, the total numbers of mice available for behavioral and biochemical studies for 
each group are presented in Table 1.  
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Table 1. Total numbers of mice included in behavioral and biochemical studies 
 5 months – behavior 
6 months - neurochemistry 
12 months – behavior 
14 months - neurochemistry 
 APP/PSEN1- APP/PSEN1+ APP/PSEN1- APP/PSEN1+ 
SVCT2+/- 
 
“SVCT2+/-” 
8 male, 7 
female 
“SVCT2+/- 
APP/PSEN1+” 
7 male, 5 female 
“SVCT2+/-” 
6 male, 5 
female 
“SVCT2+/- 
APP/PSEN1+” 
7 male, 5 female 
SVCT2+/+ 
 
“Wild-type” 
7 male, 12 
female 
“APP/PSEN1+” 
10 male, 8 female 
“Wild-type” 
8 male, 13 
female 
“APP/PSEN1+” 
9 male, 5 female 
Group names are given above group distributions. Not all mice were included in all 
biochemical tests due to quantity of brain samples available for analyses. 
 
Behavioral testing 
All behavior testing was undertaken using facilities of the Vanderbilt Murine 
Neurobehavioral Core. The experimental design is shown in Figure 3. In addition to the 
planned cognitive testing, a series of control tasks for anxiety (elevated plus maze), 
locomotor activity, and neuromuscular ability (rotarod), were also performed. If behavior in 
these control tasks were affected either by APP/PSEN1 mutations, or by vitamin C 
deficiency, it could confound interpretation of learning and memory tasks (e.g. extreme 
anxiety and hypolocomotion would limit exploration of a novel area and diminish learning 
potential). 
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Figure 3 Behavioral testing experimental design at 5 and 12 months of age. Mice were sacrificed for 
biochemical measures following behavioral testing at 6 and 14 months.  
 
 
Elevated Zero Maze. Anxiety was measured using a standard Elevated Zero Maze (San 
Diego Instruments, CA). A single 5-minute trial was filmed from above, and the exploration 
paths in open and closed zones were analyzed using AnyMaze (Stoelting Co. IL). 
Locomotor activity. Activity was measured on two consecutive days in standard locomotor 
activity chambers (approx. 30 x 30 cm, ENV-510; MED Associates, Georgia, VT, USA). 
Activity was recorded automatically for 15 minutes by the breaking of infrared beams.  
Rotarod. Motor coordination and balance were tested using a commercially available 
accelerating rotarod (Ugo Basile model 7650; Stoelting Co., Wood Dale, IL, USA) as 
described [62]. Acceleration was from 4 to 40 revolutions per minute, over the course of 4 
minutes. The time taken for the mouse to rotate on the rod (clinging to the rod and rotating 
along with it instead of remaining on top) and/or to fall, were recorded with a maximal trial 
duration of 300 s. Three trials were given per day, on 2 consecutive days. 
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Y-maze. Spontaneous alternation was measured in a single 5-minute trial in a standard Y-
maze made of clear acrylic tubing, with arms 32 cm long [62]. Alternation was defined as 
consecutive entries into three different arms (e.g. ABC, BCA).  
Olfactory learning. Olfactory learning was undertaken to assess 24-hour recall of a familiar 
scent, based on the methods described in [104]. On the initial test day mice were given two 
3-minute trials in which they were exposed to a 2.5 X 2.5 cm square of filter paper moistened 
with either water or a scent (designated the ‘familiar’ odor). Olfactory cues were cherry, 
almond, or vanilla (diluted 1/400 in water, McCormick & Co., Inc, MD). On the second day of 
testing mice were again given two trials, one with the familiar odor and one with a novel odor. 
Olfactory cues and test order were randomized. Each trial was recorded and later scored by 
two trained observers for number of visits to the scented paper, and the time spent 
investigating the paper. Decreasing investigation time of the familiar odor on day 2 compared 
to day 1, and preference for the novel odor over the familiar odor on day 2 were used to index 
memory of the familiar odor. This task was only used at 5 months due to lower exploratory 
activity and the potential for loss of olfactory ability in the older mice. 
Water maze.  Water maze testing was conducted in a 107-cm diam. pool with a circular, 
acrylic platform (10 cm diam.) in equipment as described [62]. For cued-platform testing the 
platform surface was visible above the water and a marker, visible to the mice while 
swimming, was inserted into the platform. For hidden platform testing the water was rendered 
opaque through the addition of non-toxic white paint and the platform was submerged 1 cm 
below the water. Mice were given four acquisition trials per day (max. 60 s each) for cued 
trials (3 days), and hidden platform acquisition (8 days). Sessions were captured by an 
overhead camera and analyzed using AnyMaze (Stoelting Co. IL). Twenty-four hours 
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following the final training trial a 60-s probe trial was conducted. The time spent in the target 
and non-target quadrants, number of crosses of the platform location, and time spent within 
20 cm of the platform edge were the primary dependent measures derived from the probe 
trial. Swim speed and peripheral swimming (time within 10 cm of the pool wall) were also 
assessed to determine whether differences in performance could be attributed to non-
cognitive factors. This protocol was employed to ensure that mice from both age groups, and 
all genotypes, would have sufficient opportunity to learn the platform location. Anxiety 
associated with this task can impact learning ability [105], and pre-training with the visible 
version helps to reduce anxiety through repeated exposure, and also serves to introduce the 
animals to the rule that escape from the maze is possible following location of a platform. The 
8-days of acquisition testing ensures that even at the older age group, mice are able to learn 
the spatial task, and thus, probe testing for memory is possible (which it is not if all mice are 
not given sufficient opportunity to learn the location of the platform). 
Fear Conditioning.  Fear conditioning was carried out with two specialized chambers and 
computer software (Med Associates Inc. USA). Mice were placed in conditioning chambers 
that had a plexiglass door, metal walls and a metal grid floor through which a shock could be 
delivered. These were housed within sound attenuating chambers. During the initial training 
trial mice learned to associate a 30 s shock with a 2 s electric shock (0.5 mA). There were 
three tone-shock pairings during the 8-minute trial. Twenty-four hours later, mice received a 
context-retrieval trial in which they were placed in the same testing chamber as was used the 
day before and left undisturbed for 4 minutes before being returned to the home cage. One 
hour later, the context was altered by placing a white plastic, curved ‘wall’ and floor into the 
chambers, along with a dish containing 1 ml of vanilla flavoring (McCormick, USA). Mice were 
	 23	
tested in the chamber that they had not previously been tested in. For each trial cameras 
mounted to the inside of the door of the outer containment box and computer software scored 
the mice for the amount of time spent freezing (remaining immobile). As a final control 
measure to ascertain whether genotypes were equally sensitive to the shocks, mice 
underwent shock threshold testing. They were exposed to a series of 1 second shocks of 
increasing intensity (0.075 to a maximum of 0.5 mA). Their response (flinch, run, jump and 
vocalize) was noted for each shock value. The trial was ended and no further shocks were 
given once the mouse had vocalized at a particular shock strength. 
Biochemical testing 
Following terminal anesthesia with isoflurane and cervical dislocation, the tip of the tail was 
cut off and saved for DNA extraction to confirm genotype. Mice were then decapitated and 
brains were quickly removed and hemisected sagittally. One hemisphere was immersion-
fixed in 10 % formalin for 3 days, then removed to a 10 % sucrose solution and stored at 4°C. 
The remaining brain was dissected into cortex, hippocampus, and cerebellum. All samples 
were frozen on dry ice and stored at -80°C.  
Ascorbic acid. Concentrations were measured by ion pair HPLC and electrochemical 
detection as previously described [62], except that tetrapentyl ammonium bromide was used 
as the ion pair reagent. Tissue ascorbic acid was extracted as follows. Tissue samples were 
weighed and wet tissue was homogenized in a 1.5 ml microfuge tube with a combination of 
two solutions, 25% (w/v) aqueous metaphosphoric acid and 100 mM sodium phosphate 
buffer containing 5 mM EDTA (pH 8.0), mixed together in a ratio of 2:7. A total of 10 µl of 
buffer solutions was used for each mg of tissue. The samples were then centrifuged at 
13,600 g for 4 min at 3° C, and aliquots of the clear supernatant were taken for assay of 
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ascorbic acid as described above following appropriate dilution with HPLC mobile phase. 
Malondialdehyde. Malondialdehyde was measured by homogenizing small, weighed tissue 
samples in 1 ml 5% TCA solution. Samples were centrifuged at 13 000 rpm at room 
temperature for 5 mins. 250 μl of sample was reacted with the same volume of 20 mM 
thiobarbituric acid for 35 minutes at 95 °C, followed by 10 minutes at 4 °C. Malondialdehyde 
was then specifically measured using HPLC with inline fluorescence detection of the 
malondialdehyde-thiobarbituric acid adduct [74]. 
Isoprostanes. Isoprostanes were determined by GC-MS in the Vanderbilt Eicosanoid Core 
Facility. Briefly, esterified F4-neuroprostanes were quantified by stable isotope dilution 
negative ion chemical ionization gas chromatography mass spectrometry (GC/MS) using 
[2H4]-15-F2t-isoprostane as an internal standard [106].  
Protein carbonyls. Protein carbonyls were determined by reaction with DNPH using 
previously described methods from [107] with values calculated per mg protein. 
Glutathione. Total glutathione (reduced glutathione (GSH) and oxidized glutathione (GSSG)) 
were measured using previously described methods from [108]. Briefly, cerebella were 
weighed and homogenized per protocol. Glutathione reductase (GSH) was oxidixed using 
5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB), forming yellow derivative 5′-thio-2-nitrobenzoic 
acid (TNB). Glutathione disulfide (GSSG) is recycled back to GSH using NADPH. 
Absorbance was measured at 412 nm using SynergyTM H4 Hybrid microplate reader (Biotek 
Instruments, USA). 
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ELISA (soluble/insoluble Aβ1-40 and Aβ1-42). Aβ levels were quantified using anti-human Aβ1-
40 and Aβ1-42 sandwich ELISA kits, according to the manufacturer’s instructions (Invitrogen 
Corporation, Camarillo, CA; cat. # KHB3481 & KHB3441).  
Western Blotting. GFAP was detected using previously described methods 70. Incubation with 
primary antibody - 1:1,000 anti-GFAP (Cat.#MAB360, Millipore, Bedford, MA) diluted in 
blocking buffer (5% milk, TBS-0.1% Tween 20), occurred overnight at 4°C with shaking. The 
membrane was then washed with TBS-Tween-20 and incubated with secondary antibody - 
1:20,000 anti-mouse IgG-HRP (Promega, Madison, WI) for 1 hour at room temperature 
before detection with chemiluminescence (Perkin Elmer, Waltham, MA). 
Thioflavin S. Sections (30 microns thick) were cut from the formalin-fixed hemi-brain using a 
benchtop sliding microtome (Leica) on which the brains were frozen with dry ice. Sections 
were floated in 24-well plates containing 1xPBS and then mounted on gelatin-coated, 
charged glass slides. Three to five sections per mouse, containing hippocampus and cortex 
and spaced approximately 100 microns apart were chosen for quantification of thioflavin-S 
(Sigma Aldrich, USA) positive plaques as described previously [74,109]. Digital images of the 
hippocampus and overlying cortex were taken using a fluorescent imaging microscope 
(EVOSfl, AMGmicro) at a magnification of 4X. Separate images were stitched together in 
Adobe Photoshop and the area of the hippocampus and overlying cortical areas occupied by 
amyloid plaques was determined using the freely-available Image J software (National 
Institute of Health, Bethesda, MD, USA). Quantification was performed by an experienced 
researcher who was blind to the genotype of the mice. Plaque coverage was calculated as 
percent of total region measured, in pixels.  
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Statistical analyses. Data were first checked for normality, skew and outliers (greater than 
two standard deviations above or below the mean). Where necessary, data were transformed 
with log10 transformation, or analyzed using non-parametric analyses as described in results. 
All analyses were first run with sex as a fixed variable. There were no significant differences 
according to sex so all data were collapsed and analyzed together. Normality testing, ANOVA 
and t-test were analyzed using SPSS 19.0 for MAC. Single factor (2x2) ANOVA was 
conducted with SVCT2 genotype (SVCT2+/-, SVCT2+/+), and APP/PSEN1 genotype (wild-
type, APP/PSEN1+) as the between-groups variables. Behavioral tests with multiple trials 
were analyzed with Repeated Measures ANOVAs with the same between-groups factors as 
above. Non-parametric testing was done in Graphpad Prism 5 for Mac OS X. 
 
Methods for Chapter 4 	
Table 2. Total numbers of 4-month-old mice included in mitochondrial studies 
 APP/PSEN1-  APP/PSEN1+ 
SVCT2+/- 
 
“SVCT2+/-” 
(n=18) 
*Respirometry,  
TMRE/DHF, ATP/ADP 
“SVCT2+/- APP/PSEN1+” 
(n=6) 
*Respirometry 
SVCT2+/+ 
 
“Wild-type” 
(n=31) 
*Respirometry,  
TMRE/DHF, ATP/ADP 
“APP/PSEN1+” 
(n=23) 
*Respirometry,  
TMRE/DHF, ATP/ADP 
SVCT2Tg 
 
“SVCT2Tg” 
(n=9) 
* TMRE/DHF 
 
(NOT TESTED) 
		
High-resolution respirometry. Fresh cortical tissue was mechanically homogenized in a buffer 
consisting of 200mM sucrose, 5mM HEPES, 1mM EGTA and 0.05mM saponin and protease 
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inhibitors. Sequential centrifugation was used to obtain a mitochondrial isolate 
[110,111]. Freshly isolated cortical mitochondria were assayed at 0.5mg protein/ml MiR05 
respiration buffer to a final volume of 2mL per chamber in an O2K Oxygraph (Oroboros, 
Innsbruck, Austria). Baseline oxygen uptake was established over 10 minutes and oxygen 
flux was measured and normalized to protein concentration under State 4 respiration in the 
presence of glutamate (10mM), and malate (2mM) and State 3 respiration was determined by 
the addition of ADP (2mM) [110–112] over a 10-minute time-span for each. We calculated a 
“pseudo” respiratory control ratio by normalizing oxygen consumed by isolated mitochondria 
after the addition of ADP (State 3) to the oxygen consumed at baseline in the absence of 
substrate or inhibitor (State 4). While some variation is normal and can reflect quality of 
isolate preparation, the averages per group were not significantly different by ANOVA (p= 
0.1576), though the SVCT2+/- had a lower overall mean ratio than the other groups. Where 
indicated (Fig. 3), 100μM ASC (Sigma Aldrich, USA) diluted in Miro5 was added directly to a 
closed respirometer chamber containing mitochondrial isolates after baseline oxygen uptake 
was determined. The same volume of Miro5 was added to the untreated chamber. Total 
oxygen consumption due to auto-oxidation of ASC was determined after an hour in the 
closed chamber, representing the entire duration of a respirometry experiment, and was 
found to be marginal (~5 pmol/s*ml). 
Western Blotting. Isolated mitochondria were obtained as described above and disrupted 
using RIPA buffer (Sigma Aldrich, USA) with protease inhibitors (cOmplete protease inhibitor 
cocktail, Roche, Switzerland). SVCT2 expression (SVCT2 H-70 (rabbit) sc-30114, dil. 1:1000, 
Santa Cruz Biotechnology, Inc., USA) was normalized to heat shock protein-60 (HSP-60 
(mouse) A302-844A, dil. 1:2000, Bethyl Laboratories, USA). Hippocampal tissue was 
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collected from APP/PSEN1 and SVCT2+/-;APP/PSEN1 mice at 4 and 12 months of age using  
RIPA buffer with protease inhibitors, as described above and probed for amyloid β (β –
amyloid (rabbit) D54D2, dil. 1:1000, Cell Signaling  
Technology, USA). Anti-rabbit and anti-mouse IgG-HRP conjugated secondary antibodies 
were used at 1:5000 (Promega, USA). 
Vitamin C (ASC, ascorbic acid) content. ASC was measured in cerebellum by HPLC with 
electrochemical detection as described previously [62]. Cerebellum levels are a good 
reflection of levels in cortical and hippocampal areas [113]. Values were calculated per gram 
tissue wet weight. 
Mitochondrial membrane potential and oxidative stress. Isolated mitochondria from cortical 
tissue were obtained using 230mM mannitol (Sigma Aldrich, USA), 70mM sucrose (Gibco), 
20mM HEPES (Sigma Aldrich, USA), and 0.5mM EGTA (Sigma Aldrich, USA) and 0.05mM 
saponin (Sigma Aldrich, USA) [23,114]. Isolates were resuspended in buffer without saponin 
to obtain protein concentration. Isolates were divided and 325μg incubated with 100nM 
tetramethylrhodamine, ethyl ester (TMRE, ThermoFisher Cat.#T669, ex/em:540,575nm) in 
DMEM for 15 minutes at 37°C, or 20μM dihydrofluorescein diacetate (Sigma Aldrich, USA 
Aldrich, USA, ex/em:480,520nm) in PBS with fetal bovine serum (FBS, 3%) for 30 minutes at 
37°C. Isolates incubated in TMRE were pelleted using centrifugation and pellets were 
washed in PBS/BSA (TMRE pellets) or PBS/FBS (dihydrofluorescein diacetate) twice before 
plating 100μg in triplicate on black bottom 96-well plates. TMRE quenching was assessed 
using serial dilutions of 2,4-dinitrophenol DNP). Fluorescence was measured using 
SynergyTM H4 Hybrid microplate reader (Biotek Instruments, USA).  
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ATP/ADP ratio. Measurements of ATP and ADP were conducted using an ADP/ATP Ratio 
Bioluminescent Assay Kit (ab65313 Abcam, USA) on cortical tissue. Briefly, a single-cell 
suspension was prepared using one cortical hemisphere from wild type, SVCT2+/- or 
APP/PSEN1 animals (average age 21 weeks). Tissue was dissociated using 0.5% trypsin-
EDTA, followed by DNase 1 treatment. Samples were prepared according to kit instructions 
and luminescence was measured using SynergyTM H4 Hybrid microplate reader (Biotek 
Instruments, USA). Protein concentration in each well was measured and used for 
normalization.  
 
Statistical analyses. Results are presented as mean ± SEM. Differences between SVCT2 and 
APP/PSEN1 genotypes were assessed by a two-way analysis of variance (ANOVA) with post 
hoc testing using Bonferroni tests when overall significance was obtained using SPSS. 
Student’s t-tests were made in GraphPad Prism 7.0 when comparisons were made between 
two groups. Differences in fluorescence percent change between genotypes were assessed 
by two-way ANOVA with post hoc testing using Bonferroni tests when overall significance 
was obtained using GraphPad Prism 7.0. Greater variability, and artificially elevated ASC in 
SVCT2-Tg would mask the more subtle differences in SVCT2+/- versus WT, which represents 
the human-relevant condition of mild chronic deficiency versus replete status, respectively. 
Therefore, we made the a priori decision to perform individual analyses between WT and 
SVCT2+/-, or WT and SVCT2Tg. These were performed by individual Student’s t-tests.  
	 30	
 
Methods for Chapter 5 
 
Table 3. Total number of mice used in gene expression studies 
 4 months 12 months  
 APP/PSEN1
- 
APP/PSEN1+ APP/PSEN1- APP/PSEN1+ 
SVCT2+/- “SVCT2+/-” 
(n=4) 
“SVCT2+/-;APP/PSEN1+” 
(n=4) 
“SVCT2+/-” 
(n=4) 
“SVCT2+/- ;APP/PSEN1+” 
(n=4) 
SVCT2+/
+ 
 
“Wild type” 
(n=4) 
“APP/PSEN1+” 
(n=4) 
“Wild type” 
(n=4) 
“APP/PSEN1+” 
(n=4) 	
mRNA Isolation. All reagents used to isolate mRNA were included in RNeasy Mini Kit 
(Qiagen, USA). Briefly, hippocampal tissue was dissected from 4- and 12- month old mice 
and mechanically homogenized in RLT buffer with β-mercaptoethanol. Debris were pelleted 
by centrifugation. Supernatants were mixed with 1 volume of ethanol (70%) before adding to 
spin column. Genomic DNA was removed using RNase-free DNase kit (Qiagen, USA, cat. 
79254). Column-bound mRNA was washed with RW1(1x) and RPE (2x) and eluted using 
RNase-free water.  
Gene Expression. We assessed gene expression changes in 84 genes implicated in AD 
pathogenesis and progression on hippocampal tissue collected from wild-type and 
APP/PSEN1 mice with differential SVCT2 expression at 4 and 12 months of age using 
Alzheimer’s Disease RT2 Profiler PCR Array (Qiagen, PAMM-057Z). Isolated mRNA was 
reverse transcribed to cDNA using the RT2 First Strand kit (Qiagen) and loaded on to pre-
prepared 96-well plates with RT2 SYBR Green qPCR mastermix (Qiagen).  
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Hippocampal 5-hmC Quantification.  We measured 5-hmC levels in DNA isolated from 
hippocampal tissue collected from wild-type and APP/PSEN1 mice with differential SVCT2 
expression at 4 and 12 months of age using an ELISA-based Global 5-hmC Quantification 
assay (Active Motif, cat. #55108). Absorbance was measured at 450nm using SynergyTM H4 
Hybrid microplate reader (Biotek Instruments, USA). 
Statistical analyses. Data were analyzed using GeneGlobe RT2 Data Analysis Center 
(Qiagen). Results are represented as fold-change (2^ (-ΔΔCT)) defined as the normalized 
gene expression (2^(- ΔCT)) in the Test Sample (SVCT2+/-, APP/PSEN1, SVCT2+/-
;APP/PSEN1) divided the normalized gene expression (2^ (- ΔCT)) in the Control Sample 
(wild-type). APP/PSEN1 serves as the Control Sample in comparisons made between 
APP/PSEN1 and SVCT2+/-;APP/PSEN1. The p values are calculated based on a Student’s t-
test of the replicate 2^ (- ΔCT) values for each gene in the control group and test groups 
(*p<0.05, **p<0.001, ***p<0.0001). Differences in 5-hmC quantification were analyzed using a 
2x2x2 ANOVA (Age, SVCT2 status, APP/PSEN1 status) with Bonferroni post hoc testing w		
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Chapter III: Ascorbate Deficiency in the Brain Impairs Cognition, Increases Amyloid 
Accumulation and Deposition, and Oxidative Stress in APP/ PSEN1 and Normally 
Aging Mice  
 
A large portion of the Western world may be deficient in vitamin C, and in several 
studies lower blood vitamin C correlated with cognitive impairment [66,115–117]. Under 
normal circumstances ASC is maintained at high concentrations in brain tissue where it is 
critical for maintenance of oxidative balance [118]. However, brain and CSF levels can 
decrease under conditions of prolonged deficient intake, which may create a dangerous 
oxidative imbalance during normal aging, and particularly during inflammatory 
neurodegenerative diseases such as Alzheimer’s disease. Oxidative stress is a critical 
component of Alzheimer’s disease neuropathology [119,120] and ASC deficiency is likely to 
be a major contributing factor to pathology. Several studies have thus sought to define the 
role for ASC in Alzheimer’s disease, but population studies have yielded mixed results as to 
the effectiveness of dietary supplements in older adults [67,121–123]. It is therefore critical to 
determine how prolonged sub-clinical ASC deficiency can impact normal aging and 
neurodegenerative disease from the very earliest stages of disease when pathogenic 
pathways may be more malleable.  
We generated a novel mouse model of ASC deficiency in Alzheimer’s disease by 
crossing SVCT2 heterozygous knockout mice [59] with a bigenic mouse carrying two 
mutations known to cause early-onset Alzheimer’s disease (SVCT2+/-;APP/PSEN1+). These 
mice have intracellular ASC deficiency, but normal circulating levels, since they can 
synthesize the vitamin in liver. We hypothesized that low ASC in the brain would induce 
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oxidative stress from an early age and that this would accelerate the development of 
pathological changes such as amyloid-β production and deposition, as well as the associated 
cognitive deficits.  Accumulation of reactive oxygen species is a natural part of aging and thus 
we were also interested to study the effects of low ASC on normal aging in the non-
transgenic mice. 
 
Results and Discussion 
We predicted that lower brain ASC would contribute to an environment of oxidative 
imbalance that would accelerate Alzheimer’s disease neuropathology. We tested this 
hypothesis by studying cognition, oxidative stress, and amyloidogenic changes in a mouse 
model of Alzheimer’s disease with partial ablation of vitamin C transport in the brain. 
 
Low Vitamin C disrupts memory in wild-type and APP/PSEN1+ mice. Olfactory memory 
testing was conducted in 5-month old mice. Data for this test were not normally distributed 
and therefore a log10 transformation was used on the data. Baseline exploration levels did not 
vary among the genotypes for either the water or familiar odor trials (Fs<3.68, ps>0.06). 
Habituation to the familiar odor (decreased investigation time) on day 2 compared to day 1 
was used to index 24-hour recall memory of the familiar odor for each group. A t-test was 
performed between exploration times of the familiar odor on the two test days for each group. 
As expected, all mice that did not carry APP/PSEN1 mutations showed habituation to the 
familiar odor with less exploration recorded on day 2, indicated as a positive preference score 
(day 1 - day 2 exploration) in Figure 4A, (SVCT2+/- t(14)=2.176 p=0.047; wild-type t(16)=4.15 
p<0.001, Fig. 4A (left, open bars)). APP/PSEN1+ mice showed a strong but non-significant 
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trend towards habituation of exploration (t(16)=2.035, p=0.059; white hatched bar), whereas 
no decrease was observed in SVCT2+/-APP/PSEN1+ mice (t(11)=-1.578, p=0.143; red 
hatched bar). A secondary index of memory can be derived from differences in greater 
exploration of the novel smell on day 2 compared to the previously-presented odor. Wild-type 
mice showed this pattern of behavior (t(16)= -2.149, p=0.047 Fig. 4A (right)), but the same 
differences were not observed for APP/PSEN1+ mice (t(16)=-0.337, p=0.74), nor for SVCT2+/- 
mice (t(14)=1.18, p=0.258). SVCT2+/-APP/PSEN1+ spent more time exploring the familiar 
odor than the novel odor (t(11)=3.65, p=0.004). An impairment in olfactory memory may be 
particularly relevant given that olfactory deficits in mild cognitive impairment and Alzheimer’s 
disease correlate with verbal and visual memory performance [124] and may predict the 
likelihood of further cognitive decline [125].  
Tests of spatial memory in hippocampal-dependent tasks are also very important in 
Alzheimer’s disease in which the hippocampus is so heavily compromised. Alternation 
behavior in the Y-maze is thought to reflect spatial working memory. At 5 months, mice with 
APP/PSEN1 mutations made fewer alternations than wild-type mice (F1, 55=9.09, p=0.004, 
Fig. 4B). Although the effect appeared larger in SVCT2+/-APP/PSEN1+ mice, there were no 
significant effects of SVCT2 genotype (Fs<0.87, ps>0.36). At 12 months, there were no 
differences according to APP/PSEN1 genotype (Fs<0.58, ps>0.45), however, mice with low 
vitamin C made fewer alternations (F1, 49=4.92, p=0.031, Fig. 4C). Unexpectedly, alternation 
behavior did not further decline in the older animals compared to the 5-month age group, and 
the deficit observed in the APP/PSEN1+ mice was no longer apparent at the older time point. 
The number of arm entries decreased with age, from group averages of 21.4-25.2 at 5 
months, to 15.9-20.8 in the older mice. The greatest change (a 37% decrease) was observed 
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in the APP/PSEN1+ group. It is possible that reducing the number of arms entered, and 
therefore also increasing the amount of time in each arm per entry, helps to diminish the 
cognitive demands of this task and therefore leads to improved, or at least less-impaired, 
performance.  
The older cohort of mice was also tested using conditioned fear chambers. Twenty-
four hours after training, similar levels of freezing were observed among the groups in the 
original test chamber (Fs<0.77, ps>0.39, Fig. 4D). However, when tested in a novel 
environment with the conditioned stimulus (tone), APP/PSEN1 mutant mice were significantly 
impaired, showing less freezing, compared to wild-type mice (F1, 46=4.458, p=0.04, Fig. 4E). 
There was no effect of SVCT2 genotype (Fs<0.19, ps>0.67). There were no differences 
among the groups in shock-threshold; all mice flinched or jumped, and vocalized at shocks of 
0.35mA or lower, which was below the test stimulus of 0.5 mA.  
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Figure 4 Learning and memory tasks. At 5 months of age (5M), SVCT2+/−APP/PSEN1+ mice were the only 
group to show no decrease in the interest of the familiar odor on the second day of testing (24 h recall) (A, left). 
Only wild-type mice showed evidence of a significant preference for the novel over the familiar odor on day 2. In 
contrast, SVCT2+/−APP/PSEN1+ mice spent significantly less time exploring the novel odor than the familiar 
odor (A, right). At 5 months of age, mice carrying APP/PSEN1 mutations were impaired on the Y- maze 
alternation task regardless of vitamin C status (B), whereas at 12 months of age (12M), impairments were seen 
in SVCT2+/− and SVCT2+/−APP/PSEN1+ mice compared to mice with normal vitamin C levels (C). The older 
cohort of mice was also tested in the conditioned fear paradigm. All groups spent similar time freezing during the 
4 min trial in the original training context (D). However, mice carrying APP/PSEN1 mutations spent less time 
freezing in a new context, when they heard the tone that had been the conditioned stimulus, indicating impaired 
cue recall in these mice (E). Data shown are mean +SEM ∝p < 0.05 t test between exploration of odors (time in 
seconds, log10 transformed) on two separate trials (left: familiar on day 1 versus day 2, right: novel versus 
familiar on day 2); * p < 0.05, main effect of SVCT2+/− compared to SVCT2+/+, or main effect of APP/ PSEN1+ 
compared to APP/PSEN1−. 
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More comprehensive examination of spatial learning and memory was made using the 
Morris water maze. Decreasing escape latencies across 3 days of cued (visible) platform 
testing indicated that all mice were physically able to solve the task and learn the rule that the 
platform led to escape (5M: F2, 114=90.336, p<0.001; 12M F2, 100=113.69, p<0.001, data not 
shown). Hidden platform testing was then conducted to test memory for a location within the 
pool using extra-maze cues. It is important that all mice be given sufficient opportunity to 
learn the location of the platform in order to make comparisons of memory capacity during 
the probe trial. We therefore used 8 days of task acquisition training, after which average 
escape latencies were all under 10 s in the younger mice, and under 15 s in the older mice, 
indicating learning in all groups (5M: F7, 399=39.57, p<0.001, Fig. 5A; 12M F7, 336=34.46, 
p<0.001, Fig. 5E). At 5 months APP/PSEN1 mutant mice were slightly faster overall to locate 
the platform (F1, 57=4.73, p=0.034). This result was likely driven by the slightly poorer 
performance of the SVCT2+/- mice on the first 4 days of testing, but there were no other 
significant effects of genotype (Fs<3.41, ps>0.07), and all mice were equally quick to locate 
the maze by the end of training. At 12 months there were no group differences according to 
genotype (Fs<2.61, ps>0.07).  
During the 60 s no-platform probe trial, memory is typically assessed through time 
spent swimming in each of the quadrants (target versus non-target, Fig. 5I). At both ages all 
groups showed a significant preference for the platform quadrants (Fs>4.90, ps<0.05, Figs. 
5B,F). Post hoc comparisons indicated that at both ages the wild-type mice tended to perform 
with greater accuracy than the APP/PSEN1 mice, with stronger preferences for the target 
quadrant over non-target quadrants, and the poorest performance was observed in the 
SVCT2+/-APP/PSEN1+ mice. Goal-directed swimming may be better represented by time 
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spent swimming within a defined radius of the platform edge (20 cm) and number of times the 
mouse crosses the previous platform location. At 5 months of age, mice carrying APP/PSEN1 
mutations spent less time swimming in the target zone than wild-type mice (F1, 57=9.58, 
p=0.003), but there was no additional effect of SVCT2 genotype (Fs<0.58, ps>0.45; Fig. 5C). 
At 12 months of age performance was similar across the groups (Fs<0.93, ps>0.34, Fig. 5G). 
Platform crossings did not differ among the groups at 5 months (Fs<1.14, ps>0.71, Fig. 5D). 
At 12 months, mice with low vitamin C levels made 25-50% fewer platform crossings than 
mice with normal vitamin C, which were still making approximately 4 platform crossings, 
similar to the young mice, regardless of the presence of APP/PSEN1 mutations (SVCT2 
genotype: F1, 48=6.06, p=0.017, Fig. 5H). There was no main effect of APP/PSEN1 genotype 
and no interaction (Fs<0.72, ps>0.40). Mice with low vitamin C had marginally slower swim 
speeds overall compared to normal vitamin C mice in the probe trial at 5 months of age (F1, 
57=5.175, p=0.027). This was not the case at 12 months where there were no differences in 
swim speed (Fs<2.10, ps>0.15, data not shown), and so poorer performance at this age 
cannot be attributed to physical ability. These data are in line with previous reports in mice of 
this genotype which found similar, or even larger, cognitive impairments in APP/PSEN1+ mice 
to those reported here in both water maze and Y-maze tasks [126], although other reports 
have failed to show deficits in the Y-maze at 7 months [127]. The APP/PSEN1 mouse line 
was originally developed on a hybrid background [128], and reports in mice that have been 
backcrossed for multiple generations to the C57Bl/6 background used here, typically show 
fewer deficits at early age points (e.g. 6-8 months [129,130]). 
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Figure 5 Morris water maze learning. Mice were trained on the hidden version of the water maze for 8 days to ensure that all mice had been given 
sufficient trials to learn the location of the hidden platform (A, E). Swimming locations during the no-platform probe trial were recorded and analyzed by 
group according to quadrant (target versus non-target), time spent within 20 cm of the platform edge, and crosses of the platform location, as depicted in 
(I). At both 5 months (5M) and 12 months (12M), each group showed some degree of preference for swimming in the target quadrant, although these 
preferences were clearer in mice that did not carry APP/PSEN1 mutations (B, F). Time spent in the 50 cm-diameter zone around the platform (20 cm 
from platform edge) was lower in APP/PSEN1 mutant mice at 5 months (C) but did not differ according to group at 12 months (G). Number of crosses of 
the platform location was similar across groups at 5 months (D) but was significantly lower in all mice with low vitamin C (SVCT2+/−) at 12 months of age 
(H). Data shown are mean +SEM ∝ p < 0.05 non-target quadrants compared to target quadrant for each group; * p < 0.05, Main effect of SVCT2+/− 
compared to SVCT2+/+ or main effect of APP/PSEN1+ compared to APP/PSEN1−. 
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We also assessed locomotor activity and anxiety in the mice because impairments in 
either of these areas could confound data from the tests of cognitive ability. Mice were tested 
in locomotor activity chambers for 15 min per day on two consecutive days. At both 5 and 12 
months all mice showed expected decreases in distance traveled on day 2 compared to day 
1 (F1, 59=52.2, p<0.001; F1, 50=118.89, p<0.001 Fig. 6A; B), a pattern of habituation that 
reflects memory for the testing context. Taken in combination with the results described 
above, these data suggest that cognitive impairments were not limited to behaviors 
dependent on the integrity of the hippocampal formation, and also that the impairments 
observed were not reflective of global dysfunction. Both low vitamin C and APP/PSEN1 
genotype, separately or in combination, led to poorer performance in mice under conditions 
of more active memory demands (e.g. alternation in Y-maze, probe trial in water maze), but 
not when recall of the testing context was more passive (context-dependent freezing, 
habituation to locomotor activity chambers). 
 
Low vitamin C impairs performance on the rotarod. We next assessed procedural learning 
and neuromuscular ability using the rotarod, with 3 trials conducted on each of 2 consecutive 
days. This task is known to be sensitive to effects of normal aging and as expected, 12 month 
old mice performed more poorly than younger mice, with shorter latencies to fall or rotate on 
the equipment. At both ages mice showed improvements on day 2 compared to day 1, 
indicating intact procedural learning (Fs>10.68, ps<0.002). A significant impairment was 
observed in low vitamin C mice at both ages compared to normal vitamin C mice (5M F1, 
54=6.81, p=0.012 Fig. 6E; 12 M: F1,44=10.096, p=0.003 Fig. 6F). The SVCT2 is expressed 
[131] in muscle fibers, and thus transporter deficiency could conceivably lead to weakness. 
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We did not specifically measure the decrease in vitamin C in muscle although the 
heterozygous mutation, although data from brain and other organs in these mice [60], 
suggests the mutation would result in a similar vitamin C decrease of 30-50%. Muscular 
weakness in aging is likely a combination of muscular atrophy and neuronal changes, 
particularly at the neuromuscular junction [132]. Low vitamin C in the gulo-/- model that cannot 
synthesize its own vitamin C, and is therefore vulnerable to even greater decrease in vitamin 
C based on dietary intake, has been shown to impact motor abilities in rotarod and also water 
maze in mice younger than 5 months of age, further supporting a major role for maintaining 
vitamin C to support optimal muscular strength [62,133] These mice are not known to have 
major cognitive deficits, although testing has mostly been limited to mice younger than 5 
months of age [62,133]. The deficits observed in strength and co-ordination on the rotarod in 
the younger cohort of mice suggests that vitamin C during middle age could be critical to 
maintaining good muscular health in aging. 
 
Vitamin C deficiency is associated with mild hyperactivity at 12 months but does not alter 
anxiety. At 12 months, low vitamin C (SVCT2+/-) mice were slightly hyperactive compared to 
mice with normal vitamin C (F1, 50=6.79, p=0.012), but there were no other differences 
according to genotype at either age. As a measure of anxiety in a novel environment we 
performed ‘open field’ analyses on time spent in the center of the chamber during the first 5 
min of the first trial in the locomotor activity chambers. There were no differences according 
to group on this measure of anxiety (Fs<1.96, ps>0.17, data not shown). At 5 months there 
were no differences in exploration of the elevated zero maze (Fs<2.47, ps>0.12, Fig. 6C), but 
at 12 months the SVCT2+/- and the SVCT2+/-APP/PSEN1+ mice showed further evidence of 
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mild hyperactivity in that they traveled further in the maze than mice with normal vitamin C 
levels (F1, 52=5.81, p=0.19, Fig. 6D). There were no differences on the time spent in the 
closed zones at either age (Fs<0.72, ps>0.40, data not shown).  Increased exploration was 
not observed in Y-maze arm entries in the low vitamin C mice, neither were differences 
detected in investigation time in the olfactory learning task. In combination with the lack of 
differences in anxiety measures, it is not likely that this mild difference affected cognitive 
behavior. Mild hyperactivity has been reported in this Alzheimer’s disease mouse model, but 
is not thought to be a determinant of cognitive deficits [134,135], and in a related study, 
vitamin C supplementation given in drinking water (1.0 g/L) improved a hyperactivity deficit in 
female J20 mice (bearing Swedish and Indiana mutations of APP) in the Y-maze 
spontaneous exploration task [69]. Extreme vitamin C deficiency leads to severe lethargy and 
low activity [49], but agitation and motor disturbances are features of Alzheimer’s disease that 
may be being modeled by the hyperlocomotion in mouse models [134,136,137] and it is 
therefore interesting that the modest decrease in vitamin C contributed to this increased 
activity in the older cohort of mice.  
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Figure 6 Activity, anxiety and neuromuscular coordination. Locomotor activity was tested in two 15 min 
sessions on 2 consecutive days (D1, D2). At 5 months of age (5M), there were no differences according to 
genotype (A), but at 12 months (12M), SVCT2+/− mice were slightly hyperactive compared to SVCT2+/+ mice 
with normal vitamin C levels (B). Performance on the elevated zero maze was similar among groups at 5 
months (C), but at 12 months SVCT2+/− mice traveled further than SVCT2+/+ mice (D). Performance on the 
accelerating rotarod, tested across 2 days (D1, D2), was significantly poorer in SVCT2+/− mice than SVCT2+/+ 
at both 5 months (E) and 12 months of age (F). Data shown are mean +SEM * p < 0.05, **p < 0.01, main effect 
of SVCT2+/− compared to SVCT2+/+. 
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Low vitamin C and APP/PSEN1 mutations enhance development of lipid peroxidation and 
decrease antioxidant potential. As expected, cortex vitamin C level was determined by 
SVCT2 transporter expression, and was up to 30% lower in SVCT2+/- mice in both 6 and 14 
month old mice (F1, 59=18.14, p<0.001; F1, 42=30.88, p<0.001, Fig. 7A). APP/PSEN1 
genotype had no effect on brain vitamin C level at either age (Fs<3.78, ps>0.057). A modest 
20-30% decrease in brain vitamin C is likely to be present in a significant number of humans 
with decreased dietary intake or vitamin C loss. Although direct comparisons with human 
brain levels are not possible, we have shown that mice on a low, but non-scorbutic, vitamin C 
deficiency schedule can have much larger decreases of up to 75% from normal brain, with 
almost undetectable levels in serum and liver, without suffering ill health [138]. Clinical and 
population studies of plasma vitamin C routinely report levels in the depleted and deficient 
range (<28 μM) in 10-15% of subjects, with clinical scurvy reported in some populations 
[68,139]. 
Malondialdehyde (MDA) levels followed a significant inverse relationship with brain 
vitamin C levels such that MDA was higher in mice with low vitamin C in the brain compared 
to mice with normal vitamin C at both 6 and 14 months (F1, 58=9.89, p=0.003; F1, 44=6.47, 
p=0.015, Fig. 7B). At 6 months MDA levels were also higher in APP/PSEN1+ mice than wild-
type (F1, 58=5.19, p=0.026), and although this effect was likely driven by the low value in the 
wild-type mice compared to the three other groups, there was no interaction between the 
genotypes (F1, 58=2.52, p=0.12). At 6 months, protein carbonylation was also higher in all 
mutant groups than in wild-type mice as indicated by an SVCT2 x APP/PSEN1 genotype 
interaction (F1,37=5.29, p=0.027, Fig. 7C). There were no main effects of either SVCT2 or 
APP/PSEN1 mutation alone at 6 months (Fs1, 37<2.49, ps>0.12) and there were no 
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differences among groups at 14 months (Fs1, 29<0.88, ps>0.36). At 6 months, F2-isoprostanes 
were highest in APP/PSEN1 mutant mice (F1, 37=4.56, p=0.039, Fig. 7D) with no further effect 
of SVCT2 genotype (Fs<0.12, ps>0.73). At 14 months, there were no differences among the 
groups (Fs<1.16, ps>0.29). Total glutathione (GSH+GSSG) was measured in cerebellum and 
was higher in wild-type mice than in other groups at 6 months (interaction F1, 35=7.46, 
p=0.010; main effects of SVCT2 and APP/PSEN1 alone Fs1, 35<0.85, ps>0.36, Fig. 7E). 
There were no differences among groups in 14-month old mice (Fs1, 26<2.28, ps>0.14). The 
ratio between GSH:GSSG did not differ among the groups at either age (Fs<1.52, ps>0.23, 
data not shown). Finding adverse changes in this wide range of markers of 
antioxidant/oxidative stress profile is strongly indicative that oxidative stress is an important 
driving feature of the other pathological changes observed in the mice. However, it is not the 
only mechanism that could be impacted by the lower vitamin C in the brain. Inflammatory 
response, including astrocytic activation, is another pathological change associated with 
Alzheimer’s disease. In this study, inflammatory response was indexed by measuring GFAP 
in hippocampus by semi-quantitative Western blot in 4 to 8 mice per group. At 6 months there 
were no differences in GFAP expression among the groups (Fs1, 14=1.04, ps>0.33). By 14 
months, a larger inflammatory response was observed in the APP/PSEN1 mutant mice, 
which had greater GFAP protein expression (F1, 19=4.28, p=0.05, Fig. 7F), but there were no 
further effects of SVCT2 genotype (Fs<0.40, ps>0.54). Similarly, Murakami et al. [69] 
reported decreased carbonyls following vitamin C supplementation to normal mice, and 
increased GSH, but no change in GFAP expression.  
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Figure 7 Measures of antioxidant status, oxidative stress and neuroinflammation. Mice that had 
undergone behavioral testing were sacrificed at 6 months (6M: “5 month” group) and 14 months of age (14M: 
“12 month” group). Lacking one copy of the SVCT2 successfully lowered vitamin C in the brains of SVCT2+/− 
mice (A). Low vitamin C significantly increased MDA at both ages, and at 5 months, MDA was also higher in 
APP/PSEN1+ mice (B). Protein carbonyls were also higher in all groups compared to wild-type mice at 6 
months, but by 14 months of age the levels of carbonyls were similar regardless of genotype (C). F2-
isoprostanes were increased in mice carrying APP/PSEN1 mutations but only in 6 month old mice (D). Total 
glutathione levels were higher in wild-type mice than all other groups at 6 months, but no further differences 
were seen at 14 months (E). APP/PSEN1 mutations increased GFAP expression as detected by Western blot in 
14 month old mice, although no differences were apparent in the younger cohort (F). Data shown are mean 
+SEM *p < 0.05, **p < 0.01, ***p < 0.001, Main effect of SVCT2+/− compared to SVCT2+/+; +p < 0.05, main 
effect of APP/PSEN1+ compared to APP/ PSEN1−; ∝p < 0.05 different from wild-type controls according to 
pairwise comparisons following significant interaction between genotypes in the Univariate ANOVA 
(comparisons between APP/ PSEN1+ and wild-type at each level of SVCT2, and between SVCT2+/− and 
SVCT2+/+ within APP/PSEN1+ or wild-type mice). 
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Low vitamin C enhances amyloid accumulation and deposition. Our initial hypothesis was 
that elevated oxidative stress would contribute to acceleration of other pathological features 
of Alzheimer’s disease. Total Aβ1-40 and Aβ1-42 levels in hippocampus were very low overall in 
the younger mice. Nonetheless, some differences were noted according to vitamin C level. 
Where assumption of equal variances was violated, non-parametric tests (Mann Whitney U 
test) were employed instead of a two-tailed t-test. Soluble and insoluble Aβ1-40 did not vary 
solely according to SVCT2 genotype (ps>0.077, Fig. 8A), but soluble and insoluble Aβ1-42 
were both higher in SVCT2+/-APP/PSEN1+ mice than in APP/PSEN1+ mice with normal 
vitamin C levels (soluble: Mann Whitney U=10, p=0.04; insoluble: t(13)=2.38, p=0.033, Fig. 
8C). This increase in Aβ1-42 was also reflected in the ratio of total Aβ1-42/1-40, which was 
increased in SVCT2+/-APP/PSEN1+ mice (Mann Whitney U=7, p=0.014, Fig. 8E). Thioflavin-S 
positive plaque deposits were extremely low at 6 months, and in many mice, none was visible 
in hippocampus or cortex. Accordingly, there was no difference according to SVCT2 
genotype in either area (ps>0.87, Fig. 8G, I). At 14 months, Aβ1-40 and 1-42 levels were greatly 
increased from the previous age point but no longer differed according to SVCT2 genotype 
(ps>0.53, Fig. 8B, D), possibly indicating that disease processes had advanced far enough to 
make it harder to tease apart relatively subtle differences that were evident at an earlier age. 
The ratio of total Aβ1-42/1-40 was also similar between the two groups (t(10)=0.62, p=0.55). 
However, there were significantly more thioflavin-S positive plaques observed in SVCT2+/-
APP/PSEN1+ mice than in APP/PSEN1+ mice in both hippocampus (t(19)=2.66, p=0.015) 
and cortex (t(20)=2.42, ps=0.025, Fig. 8H, I) indicating that the earlier increase in Aβ1-42 may 
have contributed to more robust amyloid seeding. 
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I. 
 
Figure 8 Measurement of amyloid β.	 Amyloid-β levels are only reported in mice that carry APP/PSEN1 
mutations. At 6 months of age (6M), soluble and insoluble amyloid-β1−40 and amyloid-β1−42 were 
very low, and insoluble amyloid proteins of both lengths were more numerous in mice with low vitamin 
C (A, C). This relationship was confirmed by the higher ratio of total amyloid-β1−42/amyloid-β1−40 in 
SVCT2+/−APP/PSEN1+ mice with low brain vitamin C (E). In the older cohort that was sacrificed at 
14 month of age (14M), amyloid- β1−40 and amyloid-β1−42 levels were much higher than in the 
younger mice, but did not differ according to group (B, D). Neither did the ratio of total amyloid-β1−42 
/amyloid-β1−40 differ according to vitamin C level at that age (F). Thioflavin-S-positive plaques were 
infrequent and small in 6 month old mice, and coverage did not vary according to vitamin C level (G). 
By 14 months of age, plaque deposits were far more numerous and were also significantly greater in 
SVCT2+/−APP/ PSEN1+ mice compared to APP/PSEN1+ mice with normal vitamin C transport (H). 
Data shown in panels A to F are mean +SEM. Data shown in panels G and H are medians, ± 
quartiles, with maximum and minimum group values represented by whiskers. *p <0.05, 
SVCT2+/−APP/PSEN1+ compared to SVCT2+/+APP/PSEN1+ mice. Example images of thioflavin-S 
stained sections are given in (I). Panels Ii and Iii show representative sections of the average percent 
coverage values for SVCT2+/−APP/PSEN1+ and SVCT2+/+APP/PSEN1+ mice at 6 months of age. 
Panels Iiii and Iiv depict representative sections of the average coverage for 14-month-old mice. 
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Six months of vitamin C supplementation lowered soluble Aβ1-42 and the Aβ1-42/1-40 
ratio, in 12-month old J20 mice, which the authors attributed to an effect on oligomerization 
[69]. Our mice had a lifelong decrease in vitamin C, and we noted changes from a much 
earlier stage of amyloid accumulation, at 6 months, although our data still fit the hypothesis 
that vitamin C affects amyloid oligomerization. In vitro, vitamin C suppressed reactivity of the 
amyloid-β A11 antibody that recognizes a particular conformation of toxic, prefibrillar Aβ 
oligomers [140]. Less specific changes in oxidative stress can also influence factors in the 
pathways for over-production of amyloid-β (e.g. BACE1 enzymatic function) [141]. Familial 
forms of Alzheimer’s disease are more typically associated with increased amyloid-β 
production, whereas sporadic Alzheimer’s disease is more likely to implicate failed clearance 
mechanisms. The altered Aβ1-42/40 ratio in young mice and increased plaques at 12 months 
suggest that vitamin C could be involved in both processes. Gulo-/- mice lack the ability to 
synthesize vitamin C, and like humans, require supplementation for survival [61]. In Gulo-/- 
mice crossed with the 5XFAD Alzheimer’s model, high dose (3.3g/L) supplemented mice 
showed less plaque deposition, and less GFAP immunoreactivity than mice with a lower, 
although not deficient, supplementation level (0.66g/L) [70]. 5XFAD mice had disrupted 
cerebral capillaries in the vicinity of plaques, but this effect was lessened with the very high 
vitamin C supplementation. In vitro vitamin C tightens endothelial cell junctions [142], which 
may be another mechanism by which vitamin C is beneficial in Alzheimer’s disease, and one 
that requires closer attention given the co-morbidity with cardiovascular disease and 
dementia. 
In our study, mice with low vitamin C, whether carrying APP/PSEN1 mutations or not, 
were exposed to potential oxidative imbalance levels for their entire lives. We found 
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detectable oxidative stress increases by 6 months of age. The same changes were evident in 
wild-type mice by 14 months of age, representing a much shorter duration of oxidative 
imbalance in those mice. The finding of learning and memory deficits in normally-aging 
SVCT2+/- mice, with deficits starting at just 5 months of age, also suggests that avoiding 
deficiency may be more useful in the prevention of cognitive decline, but does not rule out a 
role for supplementation to maintain a maximal or optimal level during aging. It is likely that 
different pathways are implicated in the damage seen in the mice with and without amyloid 
accumulation, however, it is likely that each pathway involves oxidative imbalance, either 
directly or indirectly. The extent to which specific changes are synergistic, or additive, within 
the pathological framework of Alzheimer’s disease rather than normal aging, remains to be 
established.  
The range of behavioral measures used in the present study was designed to tap into 
a number of specific brain areas; hippocampal tasks of spatial learning, amygdala-dependent 
cue-testing in the conditioned fear task, striatal-dependent locomotor activity, and cerebellar-
dependent procedural learning on the rotarod. Although the focus of Alzheimer’s disease-
related studies more typically center on hippocampal and cortical tasks, owing to the 
concentration of amyloid pathology in those areas, vitamin C is high, and preferentially 
preserved, in each of these brain areas. The behavioral and biochemical data suggest that 
antioxidant status is critical across a number of brain areas, and that each may contribute to 
the behavioral changes observed in aging and Alzheimer’s disease. Given that not all brain 
areas under oxidative stress are also associated with high amyloid load, the lack of function 
cannot solely be attributed to increased amyloidogenesis. Other potential causes of functional 
decline include changes in energy homeostasis and genetic integrity that can contribute to 
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impaired synaptogenesis and neurotransmitter function and cell death. ASC is a critical co-
factor in the biosynthesis and maintenance of collagen, which is linked to the formation of 
myelin in cell culture studies, as well as in the synthesis of catecholamines and in modulating 
receptor binding of neurotransmitters [reviewed in 96]. The specific role of vitamin C 
deficiency in each of these areas has yet to be shown but they can be attributed to a lack of 
available ASC due to the imbalance in the redox state.  
 
Summary and Conclusions 
Combined, these data suggest that chronic hypovitaminosis for vitamin C may 
accelerate the development of oxidative stress in the brain during normal aging, and also has 
a role in amyloid production, oligomerization and/or deposition. Of particular note is that the 
greatest effects of both APP/PSEN1 mutations and low vitamin C on oxidative stress and 
amyloid-β were observed before 6 months of age. In APP/PSEN1 mice this age represents 
the stage of disease pathogenesis during which significant amyloid production has been 
triggered and progression is inevitable, but what remains unclear is how ASC deficiency 
contributes during prodromal stages of the disease, at which point intervention may be 
successful. By 14 months, group differences in oxidative stress levels were less 
distinguishable, presumably eclipsed by normal changes due to aging that occur even in the 
wild-type mice. We conclude therefore that vitamin C deficiency can play a critical role in 
protection against both Alzheimer’s neuropathology and normal aging, but that greater 
attention should be paid to nutritional intakes in early middle-age rather than waiting for later 
life interventions. 
*ACS grants permission for use in dissertation.                                                                                                      
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Chapter IV: Mitochondrial dysfunction in the APP/PSEN1 mouse model and a novel 
protective role for ascorbate                                                                                                                                    
 
Increased mitochondrial dysfunction and oxidative stress are well-established features 
of the normal aging processes, and are accompanied by decreases in the activity of 
endogenous and nutrient-based antioxidants. Alterations in mitochondrial function are 
elevated at early clinical stages of sporadic Alzheimer’s disease compared with age-matched 
controls [144–146], emerging before the appearance of the classical pathological features of 
Alzheimer’s disease, such as amyloid plaques and neurofibrillary tangles [16,22,147]. 
Damage to both mitochondrial DNA and nuclear DNA have been identified in patients with 
mild cognitive impairment and early-stage Alzheimer’s disease [33,36,148]. Mitochondrial 
dysfunction, in turn, increases production of reactive oxygen species (ROS), contributing 
further to oxidative stress [10,15,149] and damage to lipids [26,38], proteins [27,46] and 
nucleic acids [150–152]. The accumulation of amyloid beta (Aβ) peptides in the Arctic APP-
over expressing mouse model decreased ATP production, impaired mitochondrial membrane 
potential, and inhibited complex IV activity, in addition to exacerbating oxidative stress 
[11,23]. Furthermore, ROS generated from mitochondrial dysfunction can drive 
amyloidogenesis and tau phosphorylation [11,32,153], thus creating a cycle that decreases 
the energy available for proper cellular function, and drives the pathology and progression of 
cell death [14,41,42]. 
Preventative strategies that slow pathological development by attenuating oxidative 
stress are projected to delay age of onset of cognitive decline. Clinical studies suggest 
antioxidant supplementation with ASC, particularly to correct states of deficiency, confers 
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some protection against the cognitive decline associated with Alzheimer’s disease [65–68]. 
ASC is a powerful antioxidant that protects against oxidative damage throughout the entire 
body. The highest concentrations of ASC are found in the brain, due to expression of SVCT2 
and efficient storage and recycling mechanisms, suggesting an important role of ASC in 
neuronal health [154]. A meta-analysis evaluating oxidative stress biomarkers confirmed 
decreased antioxidant capacity in the plasma of patients with Alzheimer’s disease, 
suggesting that antioxidant defenses are consumed more rapidly in these individuals [39]. 
Animal and cell culture studies offer additional evidence that supplementation with ASC not 
only ameliorates oxidative stress, but also mitigates the production of Aβ [69–73]. In the 
previous chapter, we reported that compromised ASC capacity increases the momentum of 
Alzheimer’s disease pathological processes with regard to soluble Aβ1-42 and Aβ1-40 peptides 
in cortical tissue from SVCT2+/-; APP/PSEN1 mice at 6 months compared with APP/PSEN1 
mice that have normal SVCT2 transporter expression [155]. Consistent with this data, other 
groups showed chronic ascorbate (ASC) supplementation resulted in a decrease in total 
soluble Aβ1-42 and a reduction in overall amyloid plaque burden in Alzheimer’s disease 
mouse models [69,70].  
It was originally believed that mitochondria took up the twice-oxidized form of ASC, 
dehydroascorbate, and reduced the molecule for use [85,156], but SVCT2 expression has 
been demonstrated on mitochondria in cell lines, indicating direct transport of ASC for a 
specific and localized requirement in that organelle [83,87]. Low ASC supplementation led to 
morphological changes in mitochondria of gulo-/-;5XFAD mice unable to synthesize their own 
ASC, compared with the high ASC supplementation group suggesting ASC is necessary for 
maintaining mitochondrial integrity by mitigating oxidative damage to the organelle [70]. It is 
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still unknown how ASC deficiency can compromise cellular function at the subcellular level in 
vivo, particularly in regard to aging and disease. In the present study we tested the 
hypothesis that decreased neuronal ASC contributes to impaired mitochondrial function and 
oxidative stress generation, and thus, contributes to the subcellular damage and cell death 
associated with Alzheimer’s disease pathogenesis. The onset of Alzheimer’s disease in the 
human population is diagnosed by progressive cognitive decline indicating that significant 
damage has already accumulated in the brain, at which point supplementation is unlikely to 
reverse damage.  
The goal of the present study was to assess the effect of ASC deficiency on 
mitochondrial facets of early disease progression. This could potentially introduce an easy 
and inexpensive lifestyle modification to slow the progression of sporadic Alzheimer’s 
disease. We measured mitochondrial respiration, membrane potential, ROS generation and 
energy production in cortical mitochondrial isolates from the APP/PSEN1 mouse model for 
Alzheimer’s disease at 4 months of age, before the emergence of cognitive deficits and 
significant amyloid deposition [155,157]. We also investigated the extent to which ASC 
affects mitochondrial function in mice with heterozygous expression of the highly selective 
SVCT2 transporter (SVCT2+/-). This mutation results in commensurate decreases in cellular 
and mitochondrial ASC concentrations. Additionally, we measured respiration after acute 
ASC administration in wild type cortical mitochondria, and membrane potential and ROS 
generation in a transgenic mouse model that over-expresses SVCT2 (SVCT2Tg), which 
results in life-long increases in intracellular ASC concentrations, in order to elucidate the 
potential contributions of supra-adequate ASC levels to mitochondrial function. 
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Results and Discussion 
Disrupted aspects of mitochondrial function during early or prodromal stages of 
Alzheimer’s disease contribute to disease progression by augmenting oxidative stress and 
cell death. We hypothesized that these detrimental aspects of the disease are accelerated by 
deficiency of intracellular ASC.  
ASC status and APP/PSEN1 drive changes in oxygen consumption during increased 
mitochondrial activity. We have previously shown that cognitive deficits and amyloidogenic 
pathologies emerge at 5-6 months in SVCT2+/−;APP/PSEN1 mice, and these features of the 
disease are more pronounced compared to APP/PSEN1 mice, suggesting that ASC deficiency 
speeds the onset and progression of the disease [155]. Expression of SVCT2 protein in 
mitochondria was decreased in mice heterozygous for the SVCT2 gene by approximately 20% 
(SVCT2: F(1,14) = 5.624, p = 0.03; Fig. 9A). The magnitude of the effect is consistent with 
decreased ASC content in mitochondria from SVCT2 heterozygous mice (t(8) = 2.766, p = .024, 
Fig. 9B). These data confirm that SVCT2 is not preferentially conserved in mitochondria and 
ASC concentration within mitochondria is primarily determined by expression of the transporter. 
Aβ peptides can interact with mitochondrial membrane proteins leading to structural and 
functional alterations, which may then result in inefficient ATP production and an increase in 
mitochondrial activity [17,18,158]. While there is little amyloid accumulation prior to 6 months in 
the APP/PSEN1 mouse model [157,159], the Aβ peptide is present and measureable at 4 
months in the APP/PSEN1 mouse model, as demonstrated qualitatively by western blot (Fig. 
9C). There is thus the potential for Aβ to interact with and compromise mitochondrial function.  
Using high-resolution respirometry, we measured oxygen consumption by mitochondria 
isolates from cortical tissue collected from wild-type, SVCT2+/-, APP/PSEN1 and 
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SVCT2+/−;APP/PSEN1 mice at 4 months of age. Three substrates (glutamate, malate and ADP) 
were added sequentially in order to maximize the amount of additional ATP that can be produced 
by oxidative phosphorylation [160], thus driving mitochondria to their full, or reserve, respiratory 
capacity. Mitochondrial isolates from SVCT2+/- mice consumed less oxygen compared to mice 
with SVCT2+/+ expression at full respiratory capacity (SVCT2: F (1, 18) = 4.892, p=0.04; Fig. 9D), 
with a trend toward less oxygen consumption emerging after the addition of glutamate and 
malate (p=0.054), suggesting that adequate ASC in the mitochondria is necessary for efficient 
energy production. ASC deficiency may, therefore, contribute to an energy deficit both within and 
outside of the context of disease. In contrast, mitochondrial isolates from APP/PSEN1 mice 
consumed significantly more oxygen compared to isolates from WT and SVCT2+/- mice that did 
not carry the transgenes at full respiratory capacity (APP/PSEN1: F(1, 18) = 10.495, p=0.005; 
Fig. 9D). These data provide strong evidence that mitochondrial function is altered in both 
SVCT2+/- and APP/PSEN1 isolates because oxygen consumption in these groups is different 
than that observed in the control group. Interestingly, oxygen consumption in the combined 
SVCT2+/−;APP/PSEN1 appeared to normalize back to rates similar to those seen in the wild-type 
control group, presumably due to competing direction of effects seen in SVCT2+/− and 
APP/PSEN1 groups separately. Nevertheless, it is important to note that while respirometry 
measures how much oxygen is consumed, this design does not describe the fate of that oxygen, 
and whether it contributes to ATP or ROS production. We therefore assessed the efficiency of 
the electron transport chain in mitochondrial isolates from the SVCT2+/− and the APP/PSEN1 
mice by measuring mitochondrial membrane potential and ATP/ADP ratios to identify individual 
contributions of each mutation [23,112,161]. We used dihydrofluorescein to measure production 
of ROS production given that disruption of the electron transport chain leads to oxidative stress. 
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Figure 9 ASC deficiency and APP/PSEN1 affect oxygen consumption in mitochondria. A) SVCT2 
expression is decreased in mitochondrial isolates from mice heterozygous for SVCT2 compared to isolates with 
wild-type SVCT2 expression (p = 0.03, n = 5-6 per group). B) ASC content is significantly lower in SVCT2+/- 
mitochondria at 4 months (p = 0.024, n = 5 per group). C) Qualitative western blot analysis demonstrates 
detectable amyloid β expression in APP/PSEN1 and SVCT2+/-;APP/PSEN1 mice at 4 months of age, that 
already appears more severe in the compound mutant mice. D) SVCT2+/- mitochondrial isolates consume less 
oxygen (p=0.04), while mitochondrial isolates from APP/PSEN1 transgenic mice consume more oxygen when at 
full respiratory capacity (p = 0.005). WT n = 6, SVCT2+/- n = 5, APP/PSEN1, SVCT2+/-;APP/PSEN1 n = 6. 
Letters indicate a main effect of SVCT2 (a,b) and APP/PSEN1 (c,d). 
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ASC status and APP/PSEN1 genotype affects mitochondrial membrane potential and ATP/ADP 
ratios and increases oxidative stress. We found that oxygen consumption in isolated 
mitochondria from the combined SVCT2+/-;APP/PSEN1 group appeared to normalize in the 
high-resolution respirometry experiment due to opposing effects of the SVCT2 and 
APP/PSEN1 mutations, rather than because the combination genotype actually reflected an 
improvement in function. We therefore made the decision to investigate the individual effects 
of APP/PSEN1 and ASC deficiency. Mitochondrial membrane potential was determined through 
TMRE accumulation in mitochondrial isolates from wild-type, SVCT2+/-, and APP/PSEN1 mice, 
which reflects the extent to which oxygen consumption results in the generation of an effective 
proton gradient. As predicted, mitochondria isolated from SVCT2+/- mice showed a decreased 
TMRE fluorescence signal compared to WT mitochondria indicating loss of membrane 
polarization (t(9)= 2.278, p = 0.048, Fig. 10A). A greater TMRE fluorescence signal was 
observed in mitochondria isolated from APP/PSEN1 cortex indicating increased polarization 
across the APP/PSEN1 mitochondrial membrane compared to WT isolates (t(13) = 2.435, p = 
0.03; Fig. 10B). These results are consistent with the pattern of oxygen consumption observed in 
SVCT2+/- and APP/PSEN1 isolates (Fig. 10D). The accumulation of TMRE at 100nM can cause 
aggregation of the fluorescent probe within the mitochondrial matrix, resulting in fluorescence 
self-quenching. To determine the directionality of the fluorescence differences observed in this 
study, the proton ionophore 2,4-dinitrophenol (DNP) was added in decreasing concentrations 
(1.0 μM, 0.5 μM, 0.1 μM) after TMRE pre-loading to dissipate mitochondrial membrane potential. 
We observed no effect of genotype and no effect of DNP concentration in the percent change in 
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fluorescence from TMRE baseline between groups (data not shown). This suggests that 
fluorescence quenching occurred in mitochondrial isolates across all genotypes, but to the same 
degree, thus quenching did not mask the overall effect.  
Mitochondrial membrane potential can affect overall energy production. We next 
determined the ATP/ADP ratio in mitochondrial isolates from WT, SVCT2+/-, and APP/PSEN1 
mice. We observed a significant decrease in the ATP/ADP ratio in APP/PSEN1 isolates 
compared to WT isolates (t(11)= 2.459, p= 0.03, Fig. 10D) and no significant difference in 
ATP/ADP ratio in the SVCT2+/- isolates compared to wild type (Fig. 10C). Based on the increase 
in oxygen consumption and mitochondrial membrane potential, an increase in the ATP/ADP ratio 
would have been expected; however the decrease supports the hypothesis that the oxygen 
being consumed is not being used efficiently toward energy production. It is suggested that ASC 
can contribute to the electron transport chain by aiding in the reduction of cytochrome c [162–
164]. ASC acts as an enzymatic co-factor with the 2-oxoglutarate-dependent dioxygenases 
and is believed to play a role in iron reduction in these reactions [52]. Given that the heme-
bound iron atoms in cytochrome c are reduced and oxidized with electron transfer, it is likely 
that ASC can assist in this redox reaction due to its low reduction potential; however, it is 
important to note that canonical cytochrome c reduction requires ubiquinol oxidation, which 
occurs in the absence of ASC. The twice-oxidized form of ASC, dehydroascorbate, appears 
to a have specific role in maintaining the redox balance within mitochondria by readily 
accepting electrons, thereby preventing leakage to the formation of ROS [156]. This is further 
evidenced by the observation that ASC concentrations increase when mitochondrial isolate 
preparations are stimulated by the addition of substrates, primarily due to reduction of 
dehydroascorbate [142]. Additionally, the similar ratios observed between WT and SVCT2+/- 
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isolates suggest that the effects of ASC deficiency on mitochondria are distinct from mechanisms 
or processes specific to the disease. Although these mechanisms have not yet been clearly 
defined, either pathway could be magnified in the increased oxidative stress environment and 
presence of amyloid associated with Alzheimer’s disease progression. 
In concurrent experiments, the mitochondria isolated from WT, SVCT2+/- and APP/PSEN1 
cortices were incubated with dihydrofluorescein to measure the generation of ROS. We observed 
a significant increase in fluorescence in SVCT2+/- mitochondrial isolates compared with WT 
isolates (t(23)= 2.312, p= 0.03, Fig. 10E) and in mitochondrial isolates from APP/PSEN1 cortex 
(t(16)= 3.447, p = 0.0033; Fig. 10F), suggesting that the oxygen being consumed is not being 
used efficiently but is rather contributing to oxidative stress in both genotypes. Superoxide, the 
primary reactive oxygen species produced through oxidative phosphorylation, is reduced to 
hydrogen peroxide by superoxide dismutase. The brain has lower enzymatic antioxidant activity 
compared to peripheral tissues [165] and ASC can therefore scavenge ROS, including 
hydrogen peroxide and hydroxyl radical, providing additional support to the endogenous 
antioxidant barrier. These observations together indicate that within the context of Alzheimer’s 
disease, which impacts energy production, ASC deficiency can exacerbate dysfunctional 
mitochondrial respiration and contribute to a redox imbalance within mitochondria.   
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Figure 10 APP/PSEN1 genotype affects mitochondrial membrane potential and increases oxidative 
stress. A) Mitochondrial isolates from SVCT2+/- mice show decreased mitochondrial membrane potential 
measured by relative fluorescence from accumulated TMRE (p = 0.049, n = 5-6 per group). B) 
Mitochondrial isolates from APP/PSEN1 transgenic mice show increased membrane potential measured 
by relative fluorescence from accumulated TMRE (p = 0.0085, n = 7-8 per group). C) The ATP/ADP ratio 
in SVCT2+/- isolates were not significantly different from WT (p= 0.195). D) The ATP/ADP ratio in 
APP/PSEN1 transgenic isolates was significantly lower than in WT isolates (p= 0.0299). E) Mitochondrial 
isolates from SVCT2+/- mice had significantly greater relative fluorescence from oxidized 
dihydrofluorescein (p = 0.03) than did mice that were wild-type for SVCT2. F) Mitochondrial isolates from 
APP/PSEN1 transgenic mice also show increased levels of ROS as measured by relative fluorescence 
from oxidized dihydrofluorescein (p = 0.038). 
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ASC increases oxygen consumption and decreases ROS generation. ASC deficiency 
resulted in decreased mitochondrial respiration and increased ROS generation, thus we 
considered whether the acute supplementation of ASC to isolated mitochondria would 
increase respiration. Mitochondria were isolated from WT cortices as above, and equal 
concentrations from a single isolation were used for both ASC-supplemented and control 
conditions in each experimental replication. Once baseline oxygen consumption was 
established, either vehicle or 100μM ASC was added to mitochondria in a closed 
respirometer chamber. As expected, the addition of ASC increased oxygen consumption 
significantly over its own baseline level and the untreated group (F(1,40)= 11.31, p= 0.0017; 
Fig. 11A). Both ASC+ and ASC- groups significantly increased respiration with the sequential 
addition of substrates until reaching full respiratory capacity (F(4,40)= 26.95, p<0.0001; Fig.  
11A).  
Using the SVCT2Tg mouse model, in which SVCT2 is globally over-expressed, we 
measured mitochondrial membrane potential and ROS generation as above. SVCT2 
expression was increased in mitochondrial isolates in the SVCT2Tg model by 17% (t(6) = 0.625, p 
= 0.55) and although this difference was not significant it was accompanied by an increase in 
mitochondrial ASC concentration (t(12) = 2.166, p = 0.05) (Fig. 11B, C). The variability of SVCT2 
expression level within the mitochondria of the SVCT2Tg mice is consistent with previously 
published data from our lab of expression and ASC level in multiple organs, including brain [103]. 
Unlike SVCT2+/- isolates, we observed no significant change in TMRE fluorescence in 
SVCT2Tg mice, indicating that a chronic increase in mitochondrial ASC did not directly affect 
membrane potential. Additionally, we observed a significant decrease in dihydrofluorescein 
fluorescence in SVCT2Tg mitochondrial isolates compared to WT isolates (t(12) = 4.414, p = 
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0.0008) indicating lower ROS production in those mice.  
While we observe no significant difference Aβ 42/40 ratio (ELISA, Abcam, USA) between 
APP/PSEN1 and SVCT2-Tg; APP/PSEN1 mice in hippocampal tissue at 5 months of age (Fig 
12A), ASC levels in SVCT2Tg; APP/PSEN1 mice cortex are ~16% lower at 5 months (p=0.14) 
and ~29% lower at 12 months (p= 0.002) compared to SVCT2Tg. Wild-type and SVCT2Tg data 
were collected at the same time, but wild-type Aβ ELISA and cortical ASC data only were 
previously presented in Chapter 3. This observation suggests that the ASC is being consumed 
more rapidly in SVCT2Tg;APP/PSEN1 mice when there is over-abundance, as this change in 
cortical concentration is not observed between WT and APP/PSEN1 mice at either 5 or 12 
months. ASC levels increase slightly between WT and APP/PSEN1, but it is important to note 
that mice biosynthesize ASC and can increase systemic levels that are limited by transporter 
expression. Interestingly, ASC levels are clearly not limited by the ability to regulate biosynthesis, 
in that mice carrying SVCT2Tg exhibit substantially greater concentrations, thus supporting a 
critical role for ASC. Together, these data suggest that the role of ASC in mitochondria is not 
directly related to driving Aβ pathology, but rather its effects may contribute to overall 
mitochondrial function and maintaining redox homeostasis, as demonstrated above.  
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Figure 11 ASC increases oxygen consumption in isolated mitochondria and decreases ROS production. 
A) The oxygen consumed by mitochondrial isolated from WT cortex was significantly increased with the addition of 
100μM ASC (p = 0.0017) compared to vehicle following establishment of baseline. . Oxygen consumption within 
groups increased with the addition of each new substrate compared to the prior condition (p < 0.0001). Asterices (*) 
indicate a main effect of ASC following addition of ASC and of each substrate B) SVCT2 xpression is only slightly 
increased, (not significant), in mitochondria isolated from SVCT2Tg mice compared to WT mitochondria (p = 0.55, n= 
5 per group). C) ASC content is significantly elevated,, in SVCT2Tg mitochondria at 4 months (p = 0.05, n = 5-9 per 
group). D) Mitochondrial isolates from SVCT2Tg mice show no difference in mitochondrial membrane potential 
measured by relative fluorescence from accumulated TMRE (p = 0.3409, n = 5-7 per group). E) Mitochondrial 
isolates from SVCT2Tg mice show a significant decrease in levels of ROS as measured by relative fluorescence from 
oxidized dihydrofluorescein (p = 0.0008, n = 6-8). 
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Figure 12 Intracellular ASC concentration is altered in SVCT2Tg ;APP/PSEN1 mice. A) Amyloid β 42/40 ratio 
is significantly greater at 12 months compared with 5 months in APP/PSEN1 and SVCT2Tg;APP/PSEN1 mice (p< 
0.0001) but does not differ according to genotype with each age group. B) Cortical ASC concentration is significantly 
elevated in SVCT2Tg mice compared to mice with normal SVCT2 expression (p=0.005) at 5 months, but at 12 months 
a significant difference is observed between SVCT2Tg and SVCT2Tg;APP/PSEN1 only (p=0.0002).
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Summary and Conclusions 
ASC is critical for mitochondrial health and ASC deficiency is a major cause of 
oxidative stress that contributes to Alzheimer’s disease risk. The data presented in the 
previous chapter demonstrated a relationship between ASC deficiency, oxidative stress and 
amyloid pathology. Here we report that ASC deficiency and the APP/PSEN1 genotype alter 
mitochondrial respiration, membrane potential, energy production and increase ROS 
generation at much earlier stages in disease progression. While optimal levels of ASC are 
unknown [154], adequate ASC supports both the redox balance within mitochondria, and 
oxygen consumption. The key features of oxidative stress and mitochondrial dysfunction that 
are elevated at prodromal stages are believed to drive disease pathology, and may provide 
potential biomarkers before the manifestation of clinical symptoms. Elderly individuals are at 
even greater risk as the activity of endogenous antioxidant enzymes decreases with age, a 
phenomenon that is exaggerated in Alzheimer’s disease suggesting that the antioxidant 
barrier is being overwhelmed by increasing oxidative stress [11,166]. However, given that 
biological changes are observed in humans long before cognitive symptoms manifest 
[24,167], ASC deficiency in mid-life may have an impact on the risk for developing AD. We 
next sought to determine whether ASC deficiency and oxidative stress influence the age of 
onset for disease-driven gene expression changes associated with the pathogenesis of AD.  
 
 
 
 
 
 
 
 *Elsevier grants permission for use in dissertation. 
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Chapter V: Early gene changes in Alzheimer’s disease are exacerbated                        
by ascorbate deficiency 
 
Gene changes that occur early in Alzheimer’s disease may be crucial in dictating the 
rate of decline in later life. Many important pathways such as energy metabolism, protein 
degradation and antioxidant defense become less efficient with age. However, the 
appearance of deficiencies in each pathway may occur more rapidly in those individuals at 
risk for developing AD, and in turn contribute to accelerated overall decline [11,12,168]. 
Early gene changes also likely represent pathways that are more amenable to 
pharmacological or lifestyle interventions. Increased oxidative stress has been associated 
with upregulation of genes related to AD. For this reason, maintaining high levels of nutrient-
based antioxidants may be an essential adjuvant therapy. ASC is a vital molecule for its 
antioxidant and enzymatic co-factor capabilities. ASC has a low reduction potential, which 
allows it to reduce most radicals and oxidants it interacts with in the aqueous phase [47,64], 
and has the ability to recycle other antioxidants such as the lipophilic antioxidant vitamin E 
[48]. In clinical studies, ascorbate supplementation decreased the prevalence of DNA 
adducts and DNA strand breaks after mutagen or carcinogen exposure, specifically when 
plasma concentrations exceeded 50μmol/L [53]. ASC deficiency is often studied in guinea 
pigs because they are incapable of ascorbate biosynthesis, similar to the human condition. 
Lykkesfeldt et al. (2007) reported increased DNA oxidation and DNA incision repair in 
neonatal guinea pigs with ASC deficiency [169]. We have previously reported that ASC 
deficiency in mice, either through heterozygous expression of the SVCT2, or through an 
inability to biosynthesize ASC (gulo-/-), is correlated with increased levels of oxidative 
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damage in the brain [59,62,113]. ASC deficient mice crossed with APP/PSEN1, show an 
accelerated pattern of both cognitive and pathological deficits compared with ASC-replete 
control, as discussed in previous chapters. SVCT2+/- mice have a life-long, 30% decrease in 
global ASC tissue concentration compared to wild-type mice [59,60], but SVCT2+/-
;APP/PSEN1 mice have significantly lower cortical ASC concentration compared with 
SVCT2+/- mice at 14 month, suggesting more rapid consumption of ASC in the brains of these 
animals due to the presence of AD pathology.  
In addition to the role of ASC as an antioxidant to directly scavenge ROS, it also 
functions as an enzymatic cofactor in 2-oxoglutarate-dependent dioxygenases (2-ODDs) 
reactions, such as TET hydroxylases [55,56,58,170], AlkB DNA repair proteins [52,171]. 
These observations indicate that compromised ASC capacity increases the momentum of AD 
pathological processes and may hasten AD-related epigenetic modification and oxidative 
DNA damage because of a diminished capacity to maintain the cellular redox balance and 
diminished availability as an enzymatic cofactor. To investigate the effect of ASC deficiency 
on AD-driven gene expression, we used a pre-designed array with 84 genes implicated in AD 
pathogenesis and progression to determine alterations in gene expression in hippocampi 
collected from wild-type and APP/PSEN1 mice with differential SVCT2 expression at 4 and 
12 months of age. Given the previous findings of increases in both oxidative stress and 
amyloid pathology at 6 months, along with the emergence of cognitive deficits at 5 months in 
the SVCT2+/-;APP/PSEN1 mice discussed in  the previous chapters, we were specifically 
interested in expression changes in genes related to amyloid generation and clearance, as 
well as neuronal health and apoptosis in order to elucidate the direct contribution of ASC 
deficiency in disease pathogenesis.  
	 71	
Results and Discussion 
Significant oxidative damage precedes the classical pathological features of AD, 
contributing to the progression of the disease [36,172]. Once established, the relationship 
between oxidative stress and AD becomes cyclical. As an antioxidant, ASC combats the 
deleterious effects oxidative stress has on DNA integrity and epigenetic regulation, and 
contributes to DNA repair mechanisms as an enzymatic cofactor, thereby maintaining 
genome integrity. We proposed that low ASC is particularly damaging in young mice with a 
greater risk for disease, and thus our primary focus was on genes known to directly govern 
disease pathology and progression at very early stages of the disease. These we divided into 
four general classifications according to functional contribution to disease pathology: (1) 
amyloid and tau pathology, (2) amyloid clearance, (3) apoptosis, and (4) neuronal health. A 
complete table of fold-regulation and p-values are reported in Table 4 and Table 5.  
The same genes were evaluated at 4 and 12 months to determine expression changes 
as a result of age and disease progression, allowing us to directly test the hypothesis that 
disease-driven genetic changes occur earlier in the context of ASC deficiency, thus 
protracting the length of abnormal disease pathology rather than exaggerating the ultimate 
level of damage. At 4 months, gene expression associated with (1) amyloidogenesis, (2) 
amyloid clearance, and (3) apoptosis are up-regulated in both of the APP/PSEN1+ groups 
compared to the wild-type group, but the magnitude of change in gene expression in the 
combined SVCT2+/−;APP/PSEN1 mice were elevated to a greater degree at this age. The 
same genes were down-regulated in young SVCT2+/− mice. These observations were 
effectively reversed by 12 months when compared to wild-type expression, presumably due 
to age-related gene expression changes in the wild type at 12 months. Specific genes and 
	 72	
their potential role in AD neuropathology are discussed in detail below.  
ASC status and APP/PSEN1 genotype drive gene expression changes related to Aβ 
generation and microtubule dynamics in young mice. We observed increased expression of the 
APP gene in both APP/PSEN1 and SVCT2+/−;APP/PSEN1 hippocampi at 4 months over wild-
type expression (Fig. 13A), as expected due to the expression of the human APP transgene in 
this mouse model. While the SVCT2+/− alone group also showed decreased APP gene 
expression compared to wild-type animals, the combined SVCT2+/−;APP/PSEN1 exhibited a 
more than 4-fold increase in expression over wild type. This observation is consistent with our 
hypothesis that ASC deficiency exacerbates AD pathology, presumably through redox 
imbalance. It is are also consistent with data discussed previously in Chapter 3 in which soluble 
Aβ1-42 and Aβ1-40 peptides were increased in cortical tissue from SVCT2+/-;APP/PSEN1 mice 
at 6 months, and Aβ plaque deposition was greater in the hippocampus and cortex at 14 
months, compared with APP/PSEN1 mice that have normal ASC transporter expression. 
We also observed an increase in gene expression related to tau proteins (microtubule-
associated proteins: Mapt, Map2) in the APP/PSEN1 and SVCT2+/−;APP/PSEN1, but not in the 
SVCT2+/− group (Fig 13A). Hyperphosphorylated tau proteins cause the aberrant microtubule 
organization associated with the formation of neurofibrillary tangles characteristic to AD 
pathogenesis, but the overexpression of tau alone has been shown to cause 
neurodegeneration in several animal models [173]. As expected Bace1, Bace2 and Psen1 
(presenilin 1) were also up-regulated as they make up the γ-secretase complex. Interestingly, 
the expression of Psen2 (presenilin 2) appears to be affected by ASC deficiency as indicated by 
the increased expression observed in the SVCT2+/− and SVCT2+/−;APP/PSEN1 groups, 
although not in the  APP/PSEN1 group (Fig 13A). Psen1 and Psen2 are both catalytically active 
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in the γ-secretase complex. Although, Aβ cleavage rates are higher with Psen1 than Psen2 
[174,175], the combination of increased expression of both could contribute to the elevated Aβ 
generation observed in earlier studies. Also of note, expression of the two homologs differs 
among tissue and in development, as indicated by distinctly different phenotypes between Psen1 
and Psen2 knock-out models [174,175].  
 
ASC status and APP/PSEN1 drive gene expression changes related to Aβ clearance in 
young mice. The low-density lipoprotein receptor-related proteins 1 and 8 (Lrp1, Lrp8) are 
specialized receptors for the endocytosis of lipoproteins and have been implicated in Aβ 
clearance. Specifically, AD patients have lower Lrp density compared with age-matched 
controls. Additionally, a single nucleotide polymorphism in Lrp C776T has been associated 
with increased risk of developing AD [176], indicating that Lrp plays a crucial role in Aβ 
clearance and degradation. Both Lrp1 and Lrp8 were upregulated in APP/PSEN1 and 
SVCT2+/−;APP/PSEN1 groups (Fig. 13B), which is consistent with an increase in amyloid 
production. Lrp1 expression in the SVCT2+/− group was also increased over wild-type (Fig. 13B). 
Lrp1 and Lrp8 are also known as Alpha-2-macroglobulin (A2m) and Apolipoprotein E (Apoe) 
receptors. A2m is implicated in Aβ degradation by directly binding to Aβ while retaining its ability 
to bind to several proteases. This induces a conformational change that exposes a binding site 
for Lrps, thereby creating a direct pathway for degradation and preventing aggregation [177]. 
A2m appears to be down-regulated more than 2.5 fold in the SVCT2+/− and APP/PSEN1 groups, 
while the magnitude of the down-regulation is not as dramatic in the SVCT2+/−;APP/PSEN1 
group at a 1.5-fold decrease (Fig. 13B). Concentrations of A2m are generally low and increased 
concentrations are associated with injury and inflammation [176]. In clinical studies, elevated 
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plasma concentrations of A2m positively correlate with increased concentrations of AD markers 
in the CSF at preclinical stages of the disease, indicating greater risk of disease progression 
[178]. The difference in fold-regulation magnitude in the SVCT2+/−;APP/PSEN1 group compared 
to the APP/PSEN1 group may indicate that A2m expression is regulated in part by ASC 
availability and progression of AD pathology.  
Apoe is involved in lipid transport and has been associated with extracellular Aβ 
clearance. Mice that overexpress APP but are null for Apoe show no Aβ plaque formation, 
while overall levels of Aβ remain unchanged. When human apoE3 and apoE4 genes are 
expressed in mice, overexpressing APP appears to affect APP processing and Aβ deposition 
[179]. Humans carrying the apoE ε4 allele have a greater risk of developing AD [180], 
perhaps due to an inherent inefficiency in the resulting protein. Interestingly, all groups show 
an increase in Apoe expression over wild-type expression (Fig. 13B); however, the role of 
Apoe may be two-fold, which would account for the apparent additive effect seen in the 
SVCT2+/−;APP/PSEN1 group. Firstly, both ASC deficiency and increased levels of Aβ result in 
increased levels of oxidative damage to membrane lipids and proteins. Apoe plays a crucial 
role in membrane repair and remodeling through transport of lipids such as cholesterol and 
phospholipids; therefore, the increased expression observed in the SVCT2+/− group may be in 
response to increased levels of lipid peroxidation, which has been reported previously by our 
group [60,155]. Secondly, increased Aβ production observed in the APP/PSEN1 and the 
SVCT2+/−;APP/PSEN1 group may deplete or overwhelm available Apoe, requiring increased 
expression of the lipoprotein.  
 Cathepsin B and D (Ctsb, Ctsd) are lysosomal proteases necessary for endocytosed or 
autophagized protein degradation, such as those facilitated by Lrps, and may play a role in Aβ 
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clearance and degradation. Ctsb appears to have a dualistic role in the literature in that it has 
been shown to degrade Aβ via the cathepsin B-cystain C axis [181]; however, studies also 
show that inhibition of Ctsb in mice expressing human wild-type APP reduces Aβ burden and 
improves memory. This is not the case for mice expressing human APP mutations associated 
with familial AD [reviewed in 35]. We observed a decrease in Cstb expression in both 
SVCT2+/− and APP/PSEN1 groups over wild-type, but an increase in the SVCT2+/−;APP/PSEN1 
group alone (Fig. 13B). This data is consistent with the increase Aβ burden discussed 
previously. Age-related Ctsd translocation to the cytosol through lysosomal permeabilization 
may play a significant role in tau degradation and APP metabolism as well as ApoE 
processing [182,183]. Lysosomal permeabilization is also associated with apoptosis due to 
translocation of proteases. In fact, we observed an increase in microtubule associated 
proteins (Mapt, Map2) in both the APP/PSEN1 and SVCT2+/−;APP/PSEN1 groups compared 
to wild-type expression (Fig. 13A). Ctsd protein localizes with Aβ plaques and is up-regulated 
in AD and mild cognitive impairment [183]. Consistent with this data, we observed an up-
regulation in Ctsd in both the APP/PSEN1 and SVCT2+/−;APP/PSEN1 groups, but decreased 
expression in the SVCT2+/− group compared to wild-type.  
 
ASC status and APP/PSEN1 genotype drive gene expression changes related to oxidative 
stress response and apoptosis in young mice. Hydroxysteroid (17-beta) dehydrogenase 10 is 
an oxioreductase localized to the mitochondria, expression of which is elevated in the brains 
of AD patients, supporting an etiological link between mitochondrial dysfunction to AD 
pathology. Hydroxysteroid (17-beta) dehydrogenase (Hsd17b10) has been shown to bind to 
intracellular Aβ oligomers, which ultimately inhibits the enzymatic efficiency of Hsd17b10 
	 76	
[184,185], resulting in alterations to neuroprotective steroid metabolism. Increased Hsd17b10 
was only observed in the SVCT2+/−;APP/PSEN1 group, presumably due to the increase in AD 
pathology hastened by ASC deficiency (Fig. 13C). Increased ROS is observed when 
Hsd17b10 binds Aβ in mitochondria, which has been shown to contribute to Aβ production 
and oxidative stress, leading to mitochondrial dysfunction and eventually cell death via 
mitochondrial membrane permeability [185]. In fact, we observed increased caspase 3 
(Casp3) expression in the SVCT2+/−;APP/PSEN1 group alone as well, indicating increased cell 
death in the ASC deficient model of AD (Fig. 13C). This is supports the hypothesis that ASC 
deficiency hastens AD pathology through amyloid-independent pathways. Interestingly, we 
also observed an increase in caspase 4 (Casp4) expression in both the APP/PSEN1 and 
SVCT2+/−;APP/PSEN1 group (Fig. 13C). Casp4 is implicated in activation of the inflammasome 
and release of the inflammatory cytokine interleukin 1 alpha (Il1a), which is also increased in both 
the APP/PSEN1 and SVCT2+/−;APP/PSEN1 group. Neuroinflammation is elevated in AD and 
contributes to the redox imbalance that leads to oxidative damage, cellular dysfunction and cell 
death associated with disease progression [9,30]. 
Gene expression of cell cycle proteins cyclin-dependent kinases 1 and 5 (Cdk1, Cdk5) 
were increased in all groups compared to wild type (Fig. 13C). Neurons are considered post-
mitotic cells and therefore do not re-enter the cell cycle; however, cell cycle proteins are 
elevated in early stages of AD [186]. As discussed previously, ROS can attack and 
oxidatively damage DNA leading to strand breaks, mutation and altered gene expression 
[37]. Cell cycle proteins are implicated in neuroplasticity, highlighting the ability of neurons to 
adapt; however, cell cycle phosphorylation and dephosphorylation also serve as checkpoints 
during mitosis and can trigger apoptosis based on compromised integrity of different cellular 
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components. Mitotic cells can repair DNA damage by re-entering the cell cycle [187], thus the 
up-regulation of cell cycle proteins Cdk1 and Cdk5 may be a conserved response to 
accumulating DNA damage and a pathway to programmed cell death. Cdk5 has also been 
implicated in aberrant tau phosphorylation [188,189]. 
 
ASC status and APP/PSEN1 drive gene expression changes related to synaptic plasticity in 
young mice. Disruptions in the cholinergic system have long been reported in AD. Choline 
acetyltranferase (Chat) activity, the enzyme necessary for biosynthesis of acetylcholine, is 
decreased in patients in late stages of AD, while an increase in Chat activity is observed in 
patients with mild cognitive impairment and early AD [190]. Several pharmacological 
interventions target the cholinergic system to preserve cognitive function, specifically 
inhibition of acetylcholinesterase-mediated (Ache) degradation of acetylcholine [159,191]. 
Ache expression was increased for both SVCT2+/− and SVCT2+/−;APP/PSEN1 while expression 
was decreased in the APP/PSEN1 group, suggesting a direct effect of ASC on the expression 
of this gene (Fig. 13D). Our group has demonstrated that acute administration of ASC 
appears to exert an inhibitory effect on Ache and facilitates neurotransmitter release from 
vesicles [48,192] resulting in improved performance in Y-maze alternation and Morris water 
maze in 12- and 24-month APP/PSEN1 mice [77]. In the present study, Chat expression 
increased across all groups compared to wild type, suggesting the up-regulation may be a 
compensatory response to insult (Fig. 13D).  
Neurotrophic factors support synaptic development and neuronal survival to promote 
learning and memory, and are neuroprotective against brain injury or insult; however, 
neurotrophic activity declines with age resulting in a decline in cognitive performance [28]. 
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Acute administration of insulin-like growth factor 2 (Igf2) via hippocampal injection or 
overexpression has been shown to encourage dendritic spine formation and neural stem cell 
proliferation, thereby improving memory, while decreasing Aβ accumulation in mouse models 
of AD [191,193]. We observed a substantial decrease in Igf2 expression (~3-fold) in SVCT2+/− 
and APP/PSEN1 groups compared to wild-type expression, but a less pronounced decrease in 
the SVCT2+/−;APP/PSEN1 group (Fig. 13D). Changes in the expression of brain-derived 
neurotrophic factor (Bdnf) are associated with different stages of AD. Some studies suggest that 
Bdnf increases in early AD and mild cognitive impairment while other studies report brain and 
serum levels are much lower in all stages of AD, significantly lower in advanced stages of AD 
compared to age-matched controls [194]. Bdnf expression was increased in SVCT2+/− and 
APP/PSEN1 over wild type, and an additive effect was observed in SVCT2+/−;APP/PSEN1, 
suggesting an up-regulation in response to insult (Fig. 13D). Additionally, only the 
SVCT2+/−;APP/PSEN1 group showed an increase in Lrp6, which is closely associated with 
Wnt/β-catenin signaling [195], and which promotes neurogenesis and synaptic plasticity through 
transcriptional activation [195,196]. Taken together, these data indicate that at 4 months of age 
mechanisms to repair or restore neuronal integrity in response to the detrimental effects of both 
ASC deficiency and AD pathology are activated through independent pathways resulting in an 
additive effect in the combined SVCT2+/−;APP/PSEN1 group.  
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Figure 13 Changes in gene expression compared to wild type at 4 months. A) Genes associated with Aβ and Tau pathology are up-regulated to a 
greater degree in ASC-deficient APP/PSEN1 mice (App: p=0.047) B) Genes associated with Aβ protein degradation are up-regulated to a greater degree 
ASC-deficient APP/PSEN1 mice (Apoe: p=0.003) C) Genes associated with apoptosis are up-regulated to a greater degree ASC-deficient APP/PSEN1 
mice. D. Genes associated with synaptic maintenance and neuronal health are up-regulated to a greater degree ASC-deficient APP/PSEN1 mice (Ache: 
p=0.012; Igf2: p=0.03). 
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Gene expression patterns differ between middle-aged and young mice. We observed a 
reversal in the expression patterns of several genes in 12-month-old mice compared to 
expression patterns in 4-month-old mice. Expression of the APP gene in the APP/PSEN1 and 
SVCT2+/−;APP/PSEN1 groups remained higher than wild type at 12 months, but not to the same 
magnitude observed in the 4-month group. Bace1, Bace2, Psen1, Psen2 and genes related to 
tau pathology (Mapt, Map2) were decreased in the APP/PSEN1 and SVCT2+/−;APP/PSEN1 
groups compared to wild type in 12-month-old mice (Fig. 14A). Interestingly, expression of App, 
Bace1, Psen1 and Mapt appear to be up-regulated SVCT2+/− at 12 months, supporting our 
hypothesis that ASC deficiency can drive AD-relevant pathology in the absence of the two 
specific mutations carried by the mice, particularly when age is also a factor. Lrp1, Lrp6, Lrp8, 
and Apoe were down-regulated, while A2m was up-regulated in APP/PSEN1 and 
SVCT2+/−;APP/PSEN1 groups compared to wild type in 12-month-old mice, consistent with 
clinical data regarding LRP expression in patients with AD (Fig. 14B).  176]. Ctsb expression 
was down regulated in APP/PSEN1 and SVCT2+/−;APP/PSEN1 in 12-month-old mice, whereas 
expression was up-regulated in the SVCT2+/− group compared to wild-type at 12 months. 
Although expression of Ctsb shows a minimal change in expression at this age, it is reported to 
remain stable across age in animal studies [182], suggesting that the observed changes are 
typical. Ctsd was significantly increased in APP/PSEN1 and SVCT2+/−;APP/PSEN1 groups 
compared to wild type in 12-month-old mice, consistent with clinical data (Fig. 14B).  [183]. Ache, 
Chat, Hsd17b10 and Caps3 were down regulated in SVCT2+/−;APP/PSEN1 mice at 12 months, 
whereas expression for these genes were increased in this group alone at 4 months. Cdk5 
expression was decreased in all groups at 12 months (Fig. 14C). Finally, Bdnf was decreased for 
all groups at 12 months, which is consistent with the literature regarding age-related decreases in 
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neurotrophic activity (Fig. 14D).  [189,194].  
 The observed reversal in expression of several genes in the APP/PSEN1 and 
SVCT2+/−;APP/PSEN1 at 12 months that had been up-regulated at 4 months may be the result 
of a compensatory mechanism. It is important to note that age-related gene expression 
changes in wild type may have contributed to the observed changes in expression patterns, 
such as magnitude of fold-change, because all data are reported relative to age-matched wild 
type expression, and we did not explicitly compare aged and young groups. However, several 
genes in the SVCT2+/- group also exhibited a reversal in gene expression directionality 
compared to wild type at 12 months (App, Bace1, Psen1, Lrp6, etc.), suggesting that within 
the context of an aging brain, ASC deficiency contributes to pathological changes when the 
disease is not present.  
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Figure 14 Changes in gene expression compared to wild type at 12 months. A) Genes associated with Aβ and Tau pathology are up-regulated to a 
greater degree in ASC-deficient mice, but down-regulated in APP/PSEN1 mice (App: p= 0.036, p= 0.018; Bace1: p= 0.026, p= 0.043 ; Psen1: p= 0.038; 
Psen2: p= 0.004, respectively) B) Genes associated with Aβ protein degradation are down-regulated in ASC-deficient and APP/PSEN1 mice (Ctsb: p= 
0.028; Ctsd: p= 0.002, p= 0.035,resp.) C) Genes associated with apoptosis are down-regulated to a greater degree in aged APP/PSEN1 mice. D. Genes 
associated with synaptic maintenance and neuronal health are down-regulated to a greater degree in aged ASC-deficient and APP/PSEN1 mice (Ache: 
p= 0.039 ; Chat p = 0.007; Bdnf: p= 0.001, resp.). 
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Global DNA methylation patterns differ between middle-aged and young mice. One 
mechanism by which gene transcription is regulated is through addition of methyl groups to 
DNA. Decreases in methylation occur naturally with age throughout the entire genome; 
however, epigenetic studies have identified differences in methylation patterns between AD 
patients and the typically aging population. DNA methylation (5-methylcytosine, 5-mC) 
effectively suppresses gene expression by inhibiting transcription factor binding at CG islands 
within gene promoter regions [197,198]. Such differences indicate that this form of gene 
regulation may contribute to the development or progression of AD [199]. A concurrent 
hypomethylation of these same genes, including BACE1 and presenilin 1 (amyloid beta 
production), as well as TNFa, NFkB, IL-6 and IL- 8 (inflammatory markers) was also detected 
under conditions of oxidative stress [37,166,189]. Similarly, a study by Chen et al. reported 
that treatment of cerebral epithelial cells with amyloid β(1-40) peptide caused global 
hypomethylation [200]. Paradoxically, the promoter region of neprilysin, an important protein 
in amyloid degradation, is shown to be hypermethylated in AD patients resulting in decreased 
expression, suggesting gene-specific regulation [200]. 
Until recently, 5-hydroxymethylcytosine (5-hmC) was believed to be a DNA oxidation 
product of 5-mC, but is now believed to be an intermediate in cytosine demethylation [201]. 5-
hmC levels are particular abundant in the brain [202], perhaps reflective of the genetic plasticity 
in the brain, in which case the presence of the stable 5-hmC intermediate effectively primes an 
inactive gene for activation [203]. Using an ELISA-based assay for global 5-
hydroxymethylcytosine (5-hmC) in hippocampus, we observed an overall increase 12 month 
mice compared to 4 month-old mice (Fig 15 F(1,22)=35.86, p<0.0001). Based on the 
hypothesis that aging is accelerated in the context of disease or ASC deficiency, we 
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compared genotypes within each age. Interestingly, we observed a main effect of 
APP/PSEN1 in global 5-hmC levels at 4 months compared to wild type (Fig 15 F(1,22)=12.17, 
p<0.002). This effect was not apparent at 12 months, presumably due to the increased 
magnitude of 5-hmC observed in the older wild-type mice compared to younger animals. 
There were no significant differences between groups at 12 months although the SVCT2+/− 
and SVCT2+/−;APP/PSEN1 showed markedly lower levels compared to the wild type and 
APP/PSEN1 groups, which have wild-type SVCT2 expression. 5-mC is oxidized to 5-hmC by 
TET enzymes [170], which utilize ASC as an enzymatic co-factor. The decrease in 5-hmC at 
12 months may be the result of decreased availability of ASC due to age- and disease-
related redox imbalance. Combined, these data suggest that oxidative stress-driven 
epigenetic modification may contribute to the pathogenesis and progression of AD. 
    
								 	
Figure 15 Hippocampal 5-hmC at 4 and 12 months. 5-hmC levels increase significantly with age (p < 0.0001). 
At 4 months, APP/PSEN1 and SVCT2+/-;APP/PSEN1 5-hmC levels were significantly greater than wild type (p 
= 0.002). 
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Summary and Conclusions 
Gene expression changes that occur in response to age, injury and disease reflect the 
brain’s ability to adapt, repair and restore function in a rapidly changing environment. This 
ability is hindered by the accumulation of oxidative stress and nutrient deficiency. We report 
here that ASC deficiency in the APP/PSEN1 mouse model of Alzheimer’s disease lead to a 
greater up-regulation of genes associated with AD pathology than in APP/PSEN1 mice with 
adequate ASC. In response, the expression of genes responsible for repairing and protecting 
the brain were up-regulated in young mice, as were genes associated with apoptosis. This 
adaptive response was lost at later stages of the disease in both groups in middle-aged mice 
due to and contributing to the detrimental cycle of oxidative stress and disease progression 
that eventually leads to cognitive dysfunction. We also observed up-regulation in genes 
associated with Aβ generation and apoptosis in middle-aged ASC deficient mice. These 
observations suggest that in familial AD, where the developing the disease is inevitable in 
those that inherit the relevant mutations, adequate ASC may delay disease pathology and 
support the protective adaptive response at very early stages of the disease. With regard to 
the sporadic form of the disease, the data presented in these chapters support the role of 
ASC deficiency in accelerating age-related and AD neuropathology, specifically that driven by 
oxidative stress. ASC deficiency is cheaply and effectively addressed through diet or 
supplementation, which provides a potential strategy to slow the progression of Alzheimer’s 
disease by attenuating the damaging effects of oxidative stress and proves to be a valuable 
addition to current Alzheimer’s disease therapies. The current data support implementation of 
antioxidant strategies at far earlier stages of disease development in order to protect against 
age-related changes that may increase the risk for developing AD.   
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Table 4 Fold-regulation and p-values for all genes across groups in 4-month-old mice.
 
Up-Down Regulation (comparing to control group)
SVCT2+/- APP/PSEN1 SVCT2+/-; APP/PSEN1
Position Symbol Fold Regulation p-value Fold Regulation p-value Fold Regulation p-value
A01 A2m -3.165 0.092 -2.559 0.081 -1.499 0.761
A02 Abca1 -1.101 0.980 1.091 0.540 1.547 0.460
A03 Ache 1.273 0.012 -1.008 0.918 2.213 0.382
A04 Adam9 -1.124 0.633 1.110 0.229 1.619 0.436
A05 Apba1 1.017 0.809 1.099 0.350 2.051 0.407
A06 Apba3 1.221 0.523 1.539 0.375 1.954 0.392
A07 Apbb1 1.520 0.032 1.477 0.470 2.716 0.340
A08 Apbb2 -1.104 0.759 1.047 0.810 1.783 0.436
A09 Aph1a -1.116 0.443 -1.046 0.798 1.875 0.403
A10 Aplp1 1.093 0.629 1.159 0.467 1.944 0.414
A11 Aplp2 -1.042 0.888 1.019 0.834 1.605 0.445
A12 Apoa1 1.389 0.186 1.016 0.872 2.176 0.379
B01 Apoe 1.293 0.003 1.028 0.755 2.366 0.310
B02 App -1.294 0.640 2.340 0.047 4.738 0.328
B03 Bace1 -1.122 0.835 1.084 0.545 1.838 0.425
B04 Bace2 -1.106 0.577 1.004 0.896 1.403 0.476
B05 Bche 1.108 0.773 1.371 0.297 1.777 0.441
B06 Bdnf 1.182 0.503 1.500 0.216 2.060 0.403
B07 Casp3 -1.375 0.287 -1.219 0.189 1.368 0.482
B08 Casp4 -1.037 0.859 1.454 0.361 1.538 0.458
B09 Cdk1 1.324 0.445 1.406 0.426 1.884 0.398
B10 Cdk5 1.144 0.558 1.291 0.395 1.844 0.416
B11 Cdkl1 -1.111 0.648 1.044 0.995 1.433 0.494
B12 Chat 1.221 0.523 1.539 0.375 1.954 0.392
C01 Clu -1.122 0.345 -1.134 0.095 1.557 0.462
C02 Ctsb -1.044 0.889 -1.047 0.740 1.820 0.431
C03 Ctsc -1.319 0.542 -1.372 0.187 1.334 0.475
C04 Ctsd -1.169 0.415 1.043 0.750 1.906 0.393
C05 Ctsg 1.221 0.523 1.539 0.375 1.954 0.392
C06 Ctsl 1.078 0.648 1.113 0.415 1.961 0.404
C07 Ep300 -1.213 0.764 1.106 0.348 1.708 0.438
C08 Ern1 -1.331 0.364 -1.069 0.557 1.713 0.438
C09 Gap43 -1.227 0.840 1.110 0.513 1.680 0.457
C10 Gnao1 -1.096 0.778 1.108 0.272 1.552 0.457
C11 Gnaz -1.018 0.964 1.174 0.250 1.878 0.419
C12 Gnb1 1.012 0.850 1.156 0.352 1.650 0.440
D01 Gnb2 1.232 0.174 1.170 0.452 2.807 0.323
D02 Gnb4 -1.002 0.738 1.027 0.736 1.812 0.428
D03 Gnb5 1.063 0.533 1.077 0.273 1.851 0.418
D04 Gng10 1.472 0.364 1.663 0.129 2.334 0.375
D05 Gng11 1.185 0.079 -1.128 0.660 1.875 0.396
D06 Gng3 1.187 0.120 1.112 0.423 1.714 0.441
D07 Gng4 1.027 0.866 1.049 0.812 1.564 0.465
D08 Gng5 1.212 0.466 1.171 0.391 2.029 0.370
D09 Gng7 -1.076 0.942 1.138 0.567 1.697 0.429
D10 Gng8 1.246 0.379 1.386 0.356 2.165 0.399
D11 Gngt1 1.221 0.523 1.539 0.375 1.954 0.392
D12 Gngt2 1.144 0.517 1.375 0.223 2.057 0.382
E01 Gsk3a -1.277 0.352 -1.202 0.148 1.508 0.473
E02 Gsk3b -1.086 0.745 1.147 0.312 1.576 0.458
E03 Hsd17b10 -1.111 0.423 -1.072 0.564 1.628 0.455
E04 Ide 1.229 0.408 1.314 0.455 1.819 0.425
E05 Igf2 -3.008 0.215 -2.828 0.027 -1.352 0.995
E06 Il1a -1.035 0.737 1.224 0.430 1.958 0.395
E07 Insr -1.076 0.827 1.064 0.207 1.778 0.424
E08 Lpl 1.098 0.615 1.487 0.277 2.096 0.351
E09 Lrp1 1.008 0.966 1.096 0.536 1.934 0.408
E10 Lrp6 -1.183 0.367 -1.062 0.447 1.542 0.439
E11 Lrp8 -1.132 0.657 1.208 0.287 1.663 0.443
E12 Mapt -1.277 0.219 1.136 0.525 1.383 0.487
F01 Mpo 1.221 0.523 1.731 0.301 1.954 0.392
F02 Map2 -1.027 0.974 1.238 0.127 1.745 0.433
F03 Nae1 1.396 0.418 1.598 0.157 2.285 0.382
F04 Ncstn -1.099 0.730 -1.049 0.580 1.570 0.459
F05 Pkp4 1.058 0.726 1.019 0.872 1.753 0.440
F06 Plat -1.256 0.274 1.015 0.876 1.469 0.465
F07 Plau -1.009 0.835 -1.004 0.902 1.529 0.477
F08 Plg 1.221 0.523 1.539 0.375 1.954 0.392
F09 Prkca -1.416 0.075 1.163 0.408 1.464 0.463
F10 Prkcb -1.164 0.200 1.066 0.630 1.554 0.457
F11 Prkcg 1.001 0.997 1.020 0.859 1.641 0.446
F12 Prkcd -1.049 0.557 -1.087 0.520 1.880 0.408
G01 Prkce -1.018 0.869 1.139 0.325 1.754 0.438
G02 Prkci -1.250 0.214 1.073 0.507 1.925 0.426
G03 Prkcq -1.704 0.185 -1.868 0.000 -1.044 0.605
G04 Prkcz 1.088 0.350 1.082 0.499 1.789 0.431
G05 Psen1 -1.044 0.793 1.139 0.326 1.644 0.443
G06 Psen2 1.147 0.121 -1.026 0.717 1.677 0.447
G07 Serpina3c 1.190 0.530 1.315 0.448 1.693 0.422
G08 Snca 1.193 0.068 1.402 0.099 2.133 0.362
G09 Sncb 1.314 0.017 1.079 0.443 1.828 0.424
G10 Ubqln1 -1.016 0.959 1.245 0.054 1.742 0.434
G11 Uqcrc1 1.314 0.066 -1.016 0.950 1.357 0.262
G12 Uqcrc2 -1.044 0.734 1.051 0.580 1.368 0.468
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Table 5 Fold-regulation and p-values for all genes across groups in 12-month-old mice.
 
Up-Down Regulation (comparing to control group)
SVCT2+/- APP/PSEN1 SVCT2+/-; APP/PSEN1
Position Symbol Fold Regulation p-value Fold Regulation p-value Fold Regulation p-value
A01 A2m -1.068 0.900 2.035 0.087 1.050 0.545
A02 Abca1 -1.009 0.876 -1.540 0.252 -1.238 0.383
A03 Ache 1.052 0.669 -1.650 0.039 -1.326 0.126
A04 Adam9 1.076 0.850 -1.257 0.514 -1.183 0.450
A05 Apba1 1.014 0.980 -1.741 0.058 -1.402 0.075
A06 Apba3 -1.257 0.007 1.092 0.505 -1.106 0.678
A07 Apbb1 1.175 0.727 -1.909 0.328 -1.534 0.553
A08 Apbb2 1.019 0.862 -1.597 0.087 -1.354 0.052
A09 Aph1a -1.002 0.995 -1.508 0.068 -1.352 0.287
A10 Aplp1 1.021 0.957 -1.378 0.071 -1.242 0.126
A11 Aplp2 1.091 0.405 -1.392 0.059 -1.242 0.038
A12 Apoa1 1.397 0.208 -1.268 0.373 1.133 0.609
B01 Apoe -1.083 0.819 -2.089 0.261 -1.449 0.329
B02 App 1.076 0.689 1.753 0.036 1.949 0.018
B03 Bace1 1.005 0.947 -1.790 0.026 -1.444 0.043
B04 Bace2 -1.115 0.830 -1.261 0.280 1.068 0.717
B05 Bche 1.019 0.947 -1.368 0.452 -1.212 0.438
B06 Bdnf -1.149 0.317 -1.317 0.116 -1.347 0.001
B07 Casp3 1.076 0.802 -1.161 0.955 -1.275 0.326
B08 Casp4 -1.104 0.160 1.324 0.153 1.187 0.109
B09 Cdk1 -1.113 0.480 3.255 0.307 2.354 0.210
B10 Cdk5 -1.018 0.893 -1.392 0.130 -1.183 0.329
B11 Cdkl1 -1.055 0.713 -1.427 0.353 -1.145 0.432
B12 Chat -1.257 0.007 1.181 0.457 -1.221 0.074
C01 Clu 1.121 0.628 -1.310 0.264 -1.204 0.356
C02 Ctsb 1.050 0.354 -1.129 0.148 -1.096 0.028
C03 Ctsc -1.021 0.781 1.308 0.060 1.133 0.182
C04 Ctsd -1.092 0.202 1.567 0.002 1.322 0.035
C05 Ctsg -1.257 0.007 1.112 0.493 -1.221 0.074
C06 Ctsl -1.007 0.989 1.091 0.112 1.052 0.283
C07 Ep300 1.119 0.671 -1.567 0.141 -1.290 0.252
C08 Ern1 -1.091 0.709 -1.315 0.492 -1.427 0.180
C09 Gap43 1.110 0.641 -2.354 0.102 -1.477 0.068
C10 Gnao1 -1.012 0.952 -1.633 0.131 -1.400 0.158
C11 Gnaz 1.057 0.655 -1.545 0.023 -1.248 0.067
C12 Gnb1 -1.053 0.848 -9.110 0.047 -1.373 0.147
D01 Gnb2 -1.121 0.949 -1.844 0.411 -1.772 0.530
D02 Gnb4 1.117 0.475 -1.564 0.039 -1.225 0.270
D03 Gnb5 -1.009 0.886 -1.694 0.006 -1.392 0.017
D04 Gng10 -1.141 0.331 -1.422 0.106 -1.313 0.111
D05 Gng11 -1.092 0.515 -1.796 0.008 -1.534 0.051
D06 Gng3 1.108 0.320 -1.441 0.001 -1.283 0.009
D07 Gng4 1.167 0.667 -1.983 0.052 -1.385 0.154
D08 Gng5 -1.098 0.123 -1.214 0.013 -1.195 0.029
D09 Gng7 -1.048 0.422 -1.529 0.052 -1.404 0.003
D10 Gng8 1.021 0.978 1.246 0.432 -1.272 0.292
D11 Gngt1 -1.257 0.007 -1.378 0.094 -1.221 0.074
D12 Gngt2 -1.072 0.688 1.388 0.141 1.189 0.357
E01 Gsk3a 1.268 0.016 -1.622 0.002 -1.299 0.011
E02 Gsk3b 1.023 0.910 -1.495 0.243 -1.366 0.253
E03 Hsd17b10 1.145 0.475 -1.313 0.131 -1.229 0.219
E04 Ide -1.149 0.399 -1.407 0.096 -1.457 0.075
E05 Igf2 -1.532 0.313 -2.794 0.241 -1.952 0.231
E06 Il1a -1.350 0.226 1.685 0.176 1.043 0.841
E07 Insr -1.106 0.641 -1.741 0.167 -1.432 0.231
E08 Lpl -1.159 0.320 -1.004 0.869 -1.018 0.888
E09 Lrp1 -1.092 0.818 -1.532 0.135 -1.432 0.277
E10 Lrp6 1.041 0.839 -1.459 0.282 -1.295 0.293
E11 Lrp8 -1.064 0.792 -1.873 0.113 -1.333 0.272
E12 Mapt 1.030 0.894 -1.534 0.110 -1.336 0.175
F01 Mpo -1.193 0.172 -1.198 0.261 -1.179 0.132
F02 Map2 -1.066 0.834 -1.616 0.193 -1.336 0.349
F03 Nae1 -1.087 0.695 -1.419 0.087 -1.261 0.172
F04 Ncstn 1.221 0.317 -1.500 0.198 -1.104 0.438
F05 Pkp4 1.077 0.423 -1.417 0.006 -1.221 0.124
F06 Plat 1.064 0.391 -1.340 0.029 -1.297 0.021
F07 Plau -1.268 0.487 1.997 0.131 1.759 0.181
F08 Plg -1.257 0.007 -1.378 0.094 -1.221 0.074
F09 Prkca -1.076 0.940 -1.588 0.218 -1.368 0.312
F10 Prkcb -1.016 0.997 -1.599 0.222 -1.412 0.260
F11 Prkcg 1.079 0.556 -1.688 0.013 -1.320 0.051
F12 Prkcd 1.427 0.147 -1.492 0.202 -1.338 0.358
G01 Prkce -1.167 0.408 -1.945 0.019 -1.682 0.021
G02 Prkci -1.500 0.340 -1.949 0.204 1.091 0.829
G03 Prkcq 1.125 0.237 -1.402 0.165 -1.257 0.020
G04 Prkcz 1.110 0.175 -1.497 0.000 -1.434 0.000
G05 Psen1 1.030 0.778 -1.467 0.103 -1.326 0.038
G06 Psen2 1.081 0.566 -1.548 0.004 -1.189 0.222
G07 Serpina3c -1.061 0.827 1.359 0.408 1.125 0.471
G08 Snca 1.005 0.939 -1.495 0.002 -1.283 0.052
G09 Sncb 1.149 0.383 -1.696 0.005 -1.322 0.049
G10 Ubqln1 -1.025 0.868 -1.597 0.146 -1.326 0.232
G11 Uqcrc1 1.011 0.979 -1.561 0.166 -1.414 0.255
G12 Uqcrc2 -1.081 0.520 -1.545 0.073 -1.275 0.148
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Chapter VI: Discussion and Future Directions 	
 
Maintaining adequate levels of cellular ASC is necessary for proper brain health and 
even mild deficiency can disrupt cellular function and efficiency. There is a direct connection 
between ASC deficiency and oxidative stress, which is considered to be a key contributor to 
the pathogenesis and progression of Alzheimer’s disease. Data from human clinical trials of 
antioxidant supplementation seldom show clear efficacy against the clinical manifestation of 
Alzheimer’s disease (such as Aβ1-42 levels, or cognitive decline [204], although supplements 
do increase vitamin levels (C and E) and decrease measures of oxidative stress in CSF after 
only one month of supplementation [205,206]. Unfortunately, such studies seldom make 
comparisons between deficient and replete states; they are typically conducted in subjects 
already suffering from mild to moderate Alzheimer’s disease, and are often limited in the 
number of measures that may be taken to assess cognition and biochemical changes. That 
dietary antioxidants can ameliorate the oxidative state in vivo has been born out many times 
[62,133], but the effects of prolonged non-scorbutic deficiency of ascorbate (and other 
antioxidants) beginning before or with disease development, has not yet been adequately 
tested in clinical populations. The findings reported here suggest that greater impetus needs 
to be given to dietary control to avoid deficiency in early to mid-adulthood, rather than late-life 
supplementation when disease processes are much more firmly established. Amyloid-β is 
detectable in brains of cognitively normal individuals as early as their mid-thirties [167]. 
We have shown here that ASC deficiency in conjunction with the APP/PSEN1 mouse 
model for Alzheimer’s disease can hasten disease pathology in aged mice, manifesting in the 
earlier emergence of amyloidogenesis and aggregation and correlated with a more rapid 
	 89	
cognitive decline than APP/PSEN1 animals with adequate ASC levels. However, the 
contribution of ASC deficiency may not be directly tied to disease pathology, but rather may 
increase the overall risk to threshold for developing the disease. ASC deficiency alone can 
impact neurological function based on the role of ASC in the synthesis and regulation of 
neurotransmitters [143]. In fact, an identifying characteristic of scurvy is lassitude, which is 
also observed in neurodegenerative diseases and psychiatric disorders [47,143]. These 
observations led to investigation into the role of ASC deficiency in early events associated 
with Alzheimer’s in prodromal APP/PSEN1 mice.  
Disruptions in energy homeostasis and mitochondrial function are observed in early 
stages of Alzheimer’s disease, but ASC deficiency also appears to impact mitochondrial 
function. According to the data presented herein, the effects of amyloid beta and the effects 
of ASC deficiency have seemingly opposing influence on mitochondrial function. Thus the 
combination of ASC deficiency and the presence of amyloid beta compound mitochondrial 
dysfunction by acting on different aspects. These observations suggest that different 
pathways are being affected by each condition. Although under experimental conditions, this 
appeared to result in a normalization of function, in vivo the result is more likely to result in a 
compounding effect on dysfunction. Amyloid beta has been shown to directly interact with 
mitochondria, which may be associated with the changes in mitochondrial morphology and 
gene expression observed in the APP/PSEN1 mouse model [16,18,19]. It has also been 
demonstrated that chronic ASC deficiency through inadequate supplementation in the 5XFAD 
mouse model for Alzheimer’s disease increases maladaptive morphology in mitochondria, but 
high ASC supplementation can protect against these morphological changes and decreases 
overall amyloid burden [70]. The result of this two-hit insult to energy homeostasis creates an 
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energy deficit that can profoundly inhibit normal cellular function rendering cells more 
vulnerable to cell death and neurodegeneration. The mechanism by which ASC supports 
mitochondrial function is not yet known. The most obvious inference is that ASC supports 
redox homeostasis within the highly metabolically active organelle, thus protecting against 
oxidative damage. However, ASC is also a co-factor for several classes of enzymes, 
including those involved in cell signaling and DNA modification and repair [56,58,169,170]. 
Further investigation is necessary to determine the specific roles for ASC in mitochondria. 
Specifically, it would be interesting to investigate the overall stability of mitochondrial DNA 
within the context of ASC deficiency given changes in gene expression associated with 
mitochondrial function are observed in young APP/PSEN1 mice [17]. Increased ROS 
production within the cell has the potential to compromise DNA in the nucleus and in 
mitochondria, leading to the cell death associated with cognitive dysfunction in AD. 
Additionally, mitochondrial DNA is not structurally protected by histones, increasing 
vulnerability to ROS attack and oxidative damage. A common 4977 base-pair deletion in 
mitochondrial DNA has been shown to increase with age [207,208] and can be used to 
assess oxidative damage. Additionally, it will be necessary to investigate DNA repair 
mechanisms and modification in the mitochondria [197]. ASC may also contribute directly to 
electron transport activity in oxidative phosphorylation [162–164]. A straightforward method to 
identify a specific site of action would be to measure oxygen consumption by isolating 
individual oxidative phosphorylation protein complexes using inhibitors and substrates in the 
presence or absence of ASC. The effects of prolonged ASC deficiency on individual 
complexes could also be investigated using this method in mitochondrial isolated from 
SVCT2+/- mice across several ages, as oxidative damage accumulates, and how this damage 
	 91	
from deficiency impacts energy production by directly measuring ATP production. Finally, the 
data presented herein describe the individual contributions of ASC deficiency (SVCT2+/-) and 
APP/PSEN1 on mitochondria, but it would be valuable to investigate the combined effects in 
the SVCT2+/-;APP/PSEN1 model across age to elucidate the scope of long term deficiency 
within the context of disease.  
Epigenetic studies have identified differences in methylation patterns in individuals 
with AD, indicating that this form of genetic modification may contribute to disease pathology 
and progression [37,198–200]. The data presented herein suggest that ASC deficiency may 
hasten disease-driven epigenetic modification through a diminished capacity in its role as an 
enzymatic cofactor and in maintaining the cellular redox balance. The most interesting aspect 
of this study is the observed acceleration in aging with regard to gene expression observed in 
the APP/PSEN1+ groups and that the magnitude of gene expression changes were impacted 
by ASC deficiency in the combined group in young, presumably prodromal, mice. This is 
evidenced by the decrease in magnitude of gene expression changes observed at 12 months 
when normal age-related expression changes in wild-type mice essentially “caught up” with 
the APP/PSEN1+ mice.  
However, it is important to note that the magnitude of expression changes in some 
genes was again impacted by ASC deficiency in aged SVCT2+/- mice. The follow-up study 
regarding global 5-hmC levels further highlighted this observation of accelerated aging in the 
APP/PSEN1+ groups in that the levels of 5-hmC were significantly elevated at 4 months, but 
showed minimal change above that at 12 months, at which point the wild type and SVCT2+/- 
were at similar levels. Given that epigenetic modification in the brain speaks to the 
adaptability of the central nervous system, these data suggest that there is heightened 
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response to the presence of disease pathology at early stages, which is then overwhelmed 
by progression of the disease. It would be interesting to compare 5-mC and 5-hmC status for 
individual genes associated with Alzheimer’s disease and the contribution of ASC deficiency 
to gather insight into how the brain is compensating or responding to the disease and how 
the additional insult changes the genetic response. A redox imbalance due to ASC deficiency 
would increase oxidation of DNA nucleotides leading to mutagenesis, single- and double-
stranded DNA breaks, because of or in combination with diminished DNA repair mechanisms 
has been documented in patients with AD [151]. Guanine is particularly vulnerable to 
oxidative attack due to its low oxidation potential, making the product 8-hydroxy-2-
deoxyguanine (8-OHdG) a substantial biomarker to measure the accumulation of damage 
[148,151,209]. Modification and removal of methyl groups restores or increases gene 
expression; however the presence of 8-OHdG in the promoter region of genes can inhibit 
transcription factor binding and/or methylation, essentially eliminating the regulation of gene 
transcriptional response to stimuli [37]. It would be interesting to measure 8-OHdG levels in 
the described groups across age to determine if the neural genetic response is being 
hindered by oxidative damage. The primary risk factor for developing Alzheimer’s disease is 
age and the phenotypic expression of aging is believed to be the result of accumulated 
oxidative damage, therefore it stands to reason that any condition that contributes to 
oxidative stress can accelerate the aging process [210]. Together, information gained from 
these studies might provide insights into the etiology of the disease in order to develop new 
and more effective therapeutic strategies and interventions.  
One further potential role for ascorbate deficiency in the cognitive decline observed in 
this study is that SVCT2+/-APP/PSEN1+ mice appear more susceptible to pharmacologically-
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induced seizures and have a higher mortality rate than the other genotypes [211]. There is a 
known association between APP mutations and seizures [212–214]. Seizures can 
independently induce additional β-amyloid production, as well as cognitive deficits, and also 
significantly increase oxidative stress [215–218]. It is, therefore, possible that unobserved 
seizures while in the home-cage could have contributed to the pathologies reported here, but 
such a relationship would have to be determined specifically in future studies.  
 
Implications  
As new insights into this disease emerge, more and more evidence suggests that the 
etiology lies not in a single event but rather in the culmination of several overlapping events 
resulting in a maladaptive neural response that ultimately leads to widespread degeneration. 
However, risk modifiers can combat maladaptive pathologies. While some conditions include 
unavoidable circumstances such as chronic disease or genetic predisposition, lifestyle 
choices often have the most profound effects on health outcomes. Nutrition and how the body 
acquires and uses nutrients have been studied for centuries and yet malnutrition is prevalent 
in modern societies. Low socioeconomic status and lack of interest and understanding lead to 
food insecurity and malnutrition in even the most industrialized areas and contribute to health 
disparities. The economic and public health advantages of promoting and supporting good 
nutrition and accessibility to food far outweigh the cost-effectiveness programs currently in 
place. It is the hope of this investigator that new research in the field of nutritional 
neuroscience continues to uncover the benefits adequate nutrition has not only in the context 
of disease but on overall health and quality of life. 
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